[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Next Article in Journal
ChsA, a Class Ⅱ Chitin Synthase, Contributes to Asexual Conidiation, Mycelial Morphology, Cell Wall Integrity, and the Production of Enzymes and Organic Acids in Aspergillus niger
Next Article in Special Issue
Associations between Genomic Variants and Antifungal Susceptibilities in the Archived Global Candida auris Population
Previous Article in Journal
Inventory of the Secondary Metabolite Biosynthetic Potential of Members within the Terminal Clade of the Fusarium solani Species Complex
Previous Article in Special Issue
Multifaceted Evaluation of Antibiotic Therapy as a Factor Associated with Candidemia in Non-Neutropenic Patients
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 9
Issue 8
10.3390/jof9080800
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Anti-Candidal Marine Natural Products: A Review

by
Arumugam Ganeshkumar
1,2,*,
Juliana Caparroz Gonçale
1,
Rajendran Rajaram
3 and
Juliana Campos Junqueira
1,*
1
Department of Biosciences and Oral Diagnosis, Institute of Science and Technology, Sao Paulo State University (UNESP), Sao Jose dos Campos 12245-000, Brazil
2
Department of Materials Physics, Saveetha School of Engineering, Saveetha Nagar, Thandalam, Chennai 602105, India
3
Department of Marine Science, Bharathidasan University, Tiruchirappalli 620024, India
*
Authors to whom correspondence should be addressed.
J. Fungi 2023, 9(8), 800; https://doi.org/10.3390/jof9080800
Submission received: 16 May 2023 / Revised: 21 July 2023 / Accepted: 26 July 2023 / Published: 28 July 2023
(This article belongs to the Special Issue New Perspectives for Candidiasis 2.0)
Browse Figures
Figure 1
<p>List of FDA-approved natural products from marine resources and their year of approval. (Source: <a href="https://www.marinepharmacology.org/" target="_blank">https://www.marinepharmacology.org/</a>, accessed on 10 July 2023).</p> "> Figure 2
<p>Marine organisms for the isolation of different marine natural products.</p> "> Figure 3
<p>Marine natural products from marine sponges. Red circle is an indicative of R group.</p> "> Figure 4
<p>Marine natural products from marine actinomycetes. Red circle is an indicative of R group.</p> "> Figure 5
<p>Marine natural products from marine fungi.</p> ">
Review Reports Versions Notes

Abstract

:
Candida spp. are common opportunistic microorganisms in the human body and can cause mucosal, cutaneous, and systemic infections, mainly in individuals with weakened immune systems. Candida albicans is the most isolated and pathogenic species; however, multi-drug-resistant yeasts like Candida auris have recently been found in many different regions of the world. The increasing development of resistance to common antifungals by Candida species limits the therapeutic options. In light of this, the present review attempts to discuss the significance of marine natural products in controlling the proliferation and metabolism of C. albicans and non-albicans species. Natural compounds produced by sponges, algae, sea cucumber, bacteria, fungi, and other marine organisms have been the subject of numerous studies since the 1980s, with the discovery of several products with different chemical frameworks that can inhibit Candida spp., including antifungal drug-resistant strains. Sponges fall under the topmost category when compared to all other organisms investigated. Terpenoids, sterols, and alkaloids from this group exhibit a wide array of inhibitory activity against different Candida species. Especially, hippolide J, a pair of enantiomeric sesterterpenoids isolated from the marine sponge Hippospongia lachne, exhibited strong activity against Candida albicans, Candida parapsilosis, and Candida glabrata. In addition, a comprehensive analysis was performed to unveil the mechanisms of action and synergistic activity of marine products with conventional antifungals. In general, the results of this review show that the majority of chemicals derived from the marine environment are able to control particular functions of microorganisms belonging to the Candida genus, which can provide insights into designing new anti-candidal therapies.

1. Introduction

Invasive and chronic fungal infections need particular medical attention since they are associated with a significant rise in treatment costs and a high fatality rate [1]. Patients who have lengthy hospital stays with compromised immune systems are more likely to get fungal infections. Candida, Aspergillus, and Cryptococcus are the three main genera of fungi that cause human diseases, ranging from superficial to invasive infections [2,3]. In contrast to other causes, they account for 90% of fungal infections that collectively afflict more than a billion people worldwide [4,5]. The four principal groups of antifungal drugs are polyenes, azoles, echinocandins, and pyrimidine analogues, which have been extensively employed in recent decades [6,7]. The therapeutic effectiveness of these antifungals depends on several factors, including host immunological response, fungal isolate origin, antifungal drug characteristics, and the emergence of drug tolerance and drug resistance. Among these factors, drug resistance is the prime concern in the world population since microorganisms can acquire several defense mechanisms against different classes of drugs [8,9]. These mechanisms can suppress the action of drugs by reducing the binding affinity with the drug target in fungal cells, leading to the overexpression or mutation in drug targets, the overproduction of hydrolytic enzymes, and alteration in effective drug concentration through the modulation of efflux activity [9,10].
Natural products are chemical molecules produced by several organisms living in different habitats [11,12]. There is a high degree of chemical diversity among biological organisms, resulting in unique structural and functional properties. Natural products have crucial roles in cellular processes, and many of them have been correlated with important biological functions [13]. The importance of natural products has been extensively reported in research focused on developing novel drugs against life-threatening conditions. The structures of natural products are entirely different from synthetic chemical products; they are more complex and have specific biological properties. The differentiation of natural products from synthetic chemical libraries provides a potential source for the identification of newer chemicals. The identification of natural products has been established since the 19th century and comprises chemical structures from terrestrial and marine environments; however, studies associated with marine natural products are limited compared with those focused on terrestrial sources.
Around 70% of Earth’s space is occupied by oceans, enriched with different floral and faunal diversity. To adapt to the harsh environment, marine organisms evolved themselves, thus directly or indirectly incorporating valuable chemical compounds with unique properties. For example, more than 30,000 chemical compounds were reported from the marine environment with anticancer properties [14,15]. Nevertheless, the extrapolation of marine compounds from the deep sea is still challenging due to many factors, including high cost, the requirement of highly sensitive instruments, time consumption, and the workforce employed [15]. Moreover, the quantity of compounds produced by an organism is relatively small, and chemical synthesis is hampered by its complex structural features. Currently, total synthesis and semi-synthesis are commonly used to overcome the supply–demand challenges of natural products. For this, biotechnological approaches are encouraged to obtain the maximum level of specific compounds using some large-scale fermentation techniques [16,17].
During the past few decades (1965–2021), only 17 of the purified chemical constituents from marine environments were recognized by US FDA for the prophylaxis of simple to life-threatening clinical conditions (Figure 1). Recently (between 2020 and 2021), lurbinectedin (ZepzelcaTM), belantamab mafodotin-blmf (Blenrep™), disitamab vedotin (Aidixi™), and tisotumab vedotin-tftv (TIVDAK™) obtained from tunicate and mollusk/cyanobacterium were approved for differential treatment of most common cancers, including metastatic cervical cancer, metastatic small cell lung cancer, and multiple myeloma [18]. In addition, there are 6 compounds in Phase III (originating from fungi, bacteria, puffer fish, tunicate, mollusk, and cyanobacteria), 15 in Phase II (originating from mollusk, cyanobacteria, sponge, and bryozoan), and 16 in Phase I (originating from mollusk, cyanobacteria, sponge, and red algae) stages of clinical trials. Besides the anticancer activity of the listed compounds, few other compounds have proven their effectiveness against chronic pain (tetrodotoxin) [19], coronavirus (plitidepsin) [20], relapsed or refractory systemic amyloidosis (STI-6129) [21], Alzheimer’s disease (bryostatin) [22], and HIV prevention and COVID-19 prophylaxis [23].
In relation to antifungal action, there are several review publications available about natural compounds from different sources; nonetheless, there are no specific publications on anti-candidal metabolites from marine resources. In light of the aforementioned antifungal resistance concerns, we were prompted to seek detailed information on marine natural products that can be effective against C. albicans and some non-albicans species. We expect that this review, which encompasses more than 150 articles from the previous three decades, can fill the knowledge gap regarding natural products targeting Candida infections. In this review, marine natural products from sponges, algae, sea cucumber, bacteria, fungi, and other organisms are presented and discussed in relation to their specific properties against Candida spp. (Figure 2).

2. Marine Natural Products

2.1. Sponges

A notable benthic community that may be found in many habitats of fresh and marine water is the sponge [24]. The generation of bioactive compounds by sponges has been closely linked to the enrichment of the sponge community with distinct populations of bacteria. Like other filter feeders, sponges never move about their surroundings in search of food and cannot flee from predators. Meanwhile, all sponge species continually produce specific substances as a defense strategy against their predators, including fish, turtles, and invertebrates [25,26]. The biological activities of these substances have been explored, and many of them showed activity against Candida spp., which are presented in Figure 3 and Table 1 and discussed below.

2.1.1. Glycoside Derivatives

Among glycoside derivatives, two compounds from the marine sponge Oceanapia sp. have been investigated: oceanalin A (C38) and B (C2). These compounds are sphingoid tetrahydoisoquinoline β-glycosides unexpectedly discovered in the organic extract from this sponge. Previous studies proved their in vitro antifungal action against C. glabrata, in which oceanalin A (C38) showed a minimum inhibitory concentration (MIC) of 30 µg/mL [43], and oceanalin B (C2) exhibited a MIC of 25 µg/mL [28]. Oceanapiside (C1), another compound purified from the methanol extract of the sponge Oceanapia phillipensis, also showed activity against C. glabrata. This compound was tested on a fluconazole-resistant strain, and its mechanism of action was associated with a disturbance in the sphingolipid pathway [27]. However, oceanapiside (C1) was not active against C. albicans and C. krusei strains [54].
In addition, tetramic acid glycoside compounds, called aurantosides, have been studied as potential antifungal agents. Aurantosides D (C46), E (C47), and F (C48) were isolated from the marine sponge Siliquariaspongia japonica. Among them, only aurantosides D (C46) and E (C47) were found to be active against C. albicans, with inhibition zones of 9.5 and 9.7 mm and MICs of 11 and 13.6 μg/mL, respectively [47]. Aurantoside K (C23) was isolated from the Fijian marine sponge Melophlus and showed a wide spectrum of antifungal activity against drug-resistant C. albicans strains, with MICs of 31.25 μg/mL and 1.95 μg/mL [39]. Aurantoside J (C32), another tetramic acid glycoside isolated from an Indonesian specimen of Theonella swinhoei, was found to be active against all the Candida strains tested (MIC >16 µg/mL), including C. albicans, C. parapsilosis, C. glabrata, and C. tropicalis [41].

2.1.2. Alkaloids

Several alkaloid compounds from marine sponges with anti-candidal activity were reported, such as hemimycalins, nakamurines, agelasines, nagelamides, zamamidine, and ceratinadins. Hemimycalins A (C13) and B (C14) are newly discovered hydantoin alkaloids from Hemimycale arabica, a marine sponge found in the Red Sea. Both of these alkaloids showed activity against Escherichia coli and C. albicans at 100 μg/disc, resulting in inhibition zones of 10–20 mm [33].
Nakamurines A (C10) and B (C11) are new non-brominated pyrrole alkaloids isolated from the sponge of Agelas nakamurai that exhibited antifungal activity against C. albicans, with a MIC of 60 μg/mL found for nakamurine B (C11) [32]. There are other relevant compounds extracted from Agelas sp., including bromopyrrole alkaloids, which demonstrated antifungal activity against C. albicans in a Caenorhabditis elegans model of candidiasis [55]; agelasines O-U (C24–C30) (diterpene alkaloids) with activity against C. albicans, exhibiting MIC values of 16–32 μg/mL [31]; nagelamides U (C18) and W (C19), which showed antifungal activity on C. albicans, with IC50 values of 4 μg/mL [37]; and nagelamides X-Z (C20–C22), which demonstrated strong activity against C. albicans (MIC values of 0.25 to 2 µg/mL) [38].
Other groups of marine sponges produce a specialized type of chemical substance known as manzamine alkaloids, which have several important biological activities. For example, zamamidine D (C9), derived from the marine sponge Amphimedon sp., showed antimicrobial activity against various pathogens, including C. albicans, with a MIC of 162 µg/mL [56]. In addition, ceratinadins A (C33) and B (C34), derived from the Okinawan sponge Pseudoceratina sp., were active against C. albicans at concentrations of 2 and 4 µg/mL, respectively [42].

2.1.3. Peptides

Most peptide compounds were isolated from the sponge Theonella sp., including theonellamide, cyclolithistide, theonegramide, and microsclerodermin. Amongst these peptides, theonellamide G (C16) is a new bicyclic glycopeptide from Theonella swinhoei that showed potential antifungal activity (MIC of 4.49 and 2.0 μM) against wild and drug-resistant strains of C. albicans, as well as high toxicity (6.0 μM) to the HCT-16 human colon adenocarcinoma cell line [35]. Similarly, theonellamide F (C54) exhibited antifungal activity against unspecific Candida spp. with MIC values of 3–12 µg/mL, and toxicity to leukemia cells (L1210 and P388) at an IC50 of 3.2 and 2.7 µg/mL [52]. Cyclolithistide A (C50), a cyclodepsipeptide, had significant antifungal activity against a reference strain of C. albicans (ATCC 24433), at a concentration of 202 µg/mL [49]. Additionally, theonegramide (C53) and microsclerodermin C (C49) also inhibited the growth of C. albicans, as reported by Bewley and Faulkner (1994) and Schmidt and Faulkner (1998), respectively [48,51]. Furthermore, there are peptides extracted from other sponges that have been reported to have antifungal activity. Discobahamin A (C56) and B (C57) (bioactive cyclic peptides) were isolated from the alcoholic extract of deep-water marine sponge Discodermia sp., but their antifungal activity against C. albicans was considered weak compared with other marine peptides [57].

2.1.4. Steroids

Studies have revealed the antifungal activity of sulfated marine steroids, specifically 29-demethylgeodisterol-3-O-sulfite (C58) and geodisterol-3-O-sulfite (C59) extracted from the bioassay-guided fractionation of the extract of Topsentia sp., on C. albicans strains resistant to fluconazole. A pair of unusual antifungal molecules were reported from the marine sponge Hippospongia lachne with superior anticandidal activity [30]. Two sterols, 9α,11α-epoxycholest-7-ene-3β,5α,6α,19-tetrol 6-acetate (C40) and agosterol A (C41), which were isolated from the marine sponge Dysidea arenaria, have also shown activity against resistant Candida strains. These steroids showed strong inhibitory activity against efflux-mediated fluconazole-resistant strains of C. albicans. They directly target both MDR1 and CDR1 to reduce fluconazole resistance [45]. Another bioactive compound, 3,5-dibromo2-(3,5-dibromo-2-methoxyphenoxy) phenol (C39), isolated from the marine sponge Dysidea herbacea, exhibited significant anti-candidal activity (MIC of 7.8 µg/mL) by binding to the ergosterol of C. albicans and disrupting its membrane permeability. This compound also induced the leakage of potassium ions from Candida cells. Moreover, it displayed in vitro activity against C. tropicalis and C. glabrata, with MIC values of 7.8 µg/mL and 15.62 µg/mL, respectively [44].

2.1.5. Terpenoids

Most bioactive terpenoids known are the group of phorbasins isolated from Phorbas sponges, including diterpenes, tetraterpenes, and sesterterpenes [58]. To date, over 11 phorbasins have been isolated and characterized with various biological activities, but only a few have exhibited antifungal activity. Two potent antifungal agents are phorboxazoles A (C51) and B (C52), which are cytostatic macrolides. These compounds have shown potent in vitro antifungal activity against C. albicans and Saccharomyces carlsbergensis at a concentration of 1 µg/disk [50]. Another example of a phorbasin with antifungal activity is phorbasin H (C17), which has been shown to prevent the yeast-to-hypha transition of C. albicans [36].
In addition to phorbasins, other terpenoids from marine sources have been identified as potential antifungal agents, such as puupehenone (C60) extracted from Stronglyophora hartmani, a deep-water marine sponge. Promisingly, puupehenone (C60) caused a disturbance in the fungal cell wall integrity pathway, along with Hsp90 function, and enhanced the antifungal activity of echinocandins against drug-resistant C. albicans and C. glabrata [59].

2.1.6. Other Chemical Compounds

Finally, other chemical compounds from sponges showed significant antifungal activity against C. albicans, such as pseudoceratins A (C36) and B (C37) (bicyclic bromotyrosins) isolated from Pseudoceratina purpurea; pseudoceroxime A-C (C3–C5), and pseudocerolide D and E (C6, C7) (new bromotyrosine derivatives) extracted from Pseudoceratina sp. [60,61]; non-brominated racemic pyrrole derivatives from Agelas nakamurai [32]; and halichondramide (C55) from Chondrosia corticate [62].

2.2. Algae

Currently, there are over a million species of algae already known on Earth. Besides maintaining the CO2 levels and preventing global warming, algae are important sources of metabolites with nutritional and health benefits. Many of these metabolites present antimicrobial action and are of great interest to the pharmaceutical industry. In addition, the metabolic plasticity of algae facilitates culture development and consequently the production of pharmacological substances at a large scale. It is known that among the red, green, and brown algae, the red algae provide the greatest number of bioactive substances, such as polysaccharides (like alginate and agar), lipids, polyphenols, steroids, glycosides, flavonoids, tannins, alkaloids, and triterpenoids [29].
Indeed, most compounds with anti-candidal activity were extracted from red algae (Table 2), including Q-griffithsin (Q-GRFT) (61), a lectin derived from Griffithsia sp. alga, which exhibited a broad of spectrum antifungal activity against C. albicans, C. glabrata, C. parapsilosis, C. krusei, and C. auris [63]. In a murine model of vaginal candidiasis, Q-GRFT treatment reduced the fungal burden and enhanced the clearance of the infection without affecting immune cell phenotypes [64]. Similarly, callophycin A (C62), a natural product of red alga Callophycus oppositifolius, was found to suppress C. albicans growth and decrease fungal burden in vaginal candidiasis in animal models, with significant reductions in proinflammatory markers [65]. On the other hand, 10-hydroxykahukuene B (C63), 9-deoxyelatol (C64), isodactyloxene A (C65), and laurenmariallene (C66) from the species of red alga Laurencia mariannensis did not exhibit good anti-candidal activity [66].
Compounds extracted from green algae have also been explored for the identification of new antifungal agents. For example, the chemical extraction of the green alga Caulerpa racemosa resulted in two rare para-xylene derivatives caulerprenylols A (C92) and B (C93). In vitro assay revealed that caulerprenylol B (C93) had a broad spectrum of antifungal activity against C. glabrata, Trichophyton rubrum, and Cryptococcus neoformans [72].

2.3. Sea Cucumber

Sea cucumbers have great medicinal value in China and other Asian countries, where they have been used as tonic food for thousands of years. Currently, it is known that these animals can produce important natural products with potential antifungal action (Table 3). Among these species, triterpene glycosides are particularly noteworthy.
A new sulfated triterpene glycoside, named coloquadranoside A (C94), was obtained from the sea cucumber Colochirus quadrangularis. This compound was effective against C. albicans, C. tropicalis, and C. parapsilosis, with MIC ranges of 4–25, 8–30, and 4–32 μg/mL, respectively. Interestingly, it was also found to be cytotoxic for tumor cell lines and had immunomodulatory activity [79]. Non-sulfated triterpene glycosides have also been investigated, including 10 new saponins called coustesides A–J (C99–C108) extracted from Bohadschia cousteaui. These compounds had antifungal action against C. albicans, with their zone of inhibition ranging from 10.7 ± 0.05 to 18.0 ± 0.01 [80]. Likewise, other new triterpene glycosides were extracted from Stichopus variegates: variegatusides C–F (C109–C112), variegatusides A (C113), B (C114), and holothurin B (C133). Amongst these compounds, variegatuside D (110) was the most effective against C. albicans, C. pseudotropicalis, and C. parapsilosis, with a MIC of 3.40 μg/mL [81].
Furthermore, many other triterpene glycosides with activity against Candida species have been identified, including arguside F (C123), impatienside B (C124), and pervicoside D (C125) from sea cucumber Holothuria axiloga; marmoratoside A (C126) and B (C127), impatienside A (C130), and bivittoside D (C131) from Bohadschia marmorata [83,84]; and holothurin B (C133) from sea cucumber Actinopyga lecanora [86].

2.4. Bacteria

Marine bacteria live in an extremely complex environment with huge diversity. The ocean column consists of approximately 106 bacterial cells per milliliter of water [87]. Due to genomic adaptability to complex environments, they can exert multiple functions and produce several biologically active molecules [88]. Thereby, marine bacteria can provide sustainably active pharmacological ingredients without harming biodiversity. For these reasons, marine microbes have been recognized as a source of bioactive compounds, gaining great attention among pharmaceutical researchers.

2.4.1. Actinomycetes

Actinomycetes are Gram-positive filamentous bacteria that are known for their ability to produce a wide range of bioactive compounds, including antifungal metabolites [89]. These bacteria are commonly found in soil, but they can also colonize other niches such as water, plants, and animals. The genera that produce the most commercially important biomolecules are Streptomyces, Nocardia, Saccharopolyspora, Amycolatopsis, Micromonospora, and Actinoplanes [90,91]. The detailed structure of some important natural products from marine Actinomycetes is presented in Figure 4 and Table 4.
Among the aforementioned genera, Streptomyces has gained more attention. The ability of Streptomyces to produce antifungal metabolites is associated with their complex genome, which contains numerous biosynthetic gene clusters that encode the production of a variety of secondary metabolites. The number of secondary metabolites has continuously increased in response to the emergence of tools and bioinformatic resources and the enhancement of deep-sea exploration technology. However, information regarding biosynthetic gene clusters still needs further investigation, such as the use of next-generation sequencing methods to obtain the genetic data of the target organisms [117]. The antifungal compounds from Streptomyces are mainly polyenes, macrolides, and peptides, which have potent activity against a broad spectrum of fungal pathogens [118,119,120]. Several examples are cited below.
Streptomyces antibioticus OUCT16-23 strain isolated from a deep-sea sediment sample produces macrolides that displayed antifungal activity against C. albicans [92]. Streptomyces sp. ZZ446 from coastal soil produces different compounds, namely streptopyrazinones A-D (C157–C160), which exhibited activity against C. albicans and methicillin-resistant Staphylococcus aureus [100,121]. Caniferolides A-D (C148–C151) from marine-derived Streptomyces caniferus CA-271066 showed antifungal activity against C. albicans, with MIC values ranging from 0.5 to 2.0 µg/mL, which were comparably lesser than the MIC of amphotericin B (2–4 µg/mL). Despite its antifungal activity, caniferolides had a high antiproliferative activity on tumor cell lines [97]. Streptomyces xinghaiensis SCSIO S15077 produce tunicamycin derivatives with antifungal activity against both fluconazole-resistant and sensitive C. albicans isolates, with emphasis on tunicamycin C3 (C144), which showed MIC values of 4 and 2 μg/mL. A bioassay-guided fraction from Streptomyces sp. YG7 yielded two new epimers of cycloheximide with moderate activity against C. albicans (a MIC value of 62.5) [98,122].
Many other antifungal compounds produced by Streptomyces spp. have been isolated, including nitricquinomycins A–C (C154–C156) [99]; rocheicoside A (C171) [103]; 28-N-methylikaguramycin (C176), isoikarugamycin (C177), and ikarugamycin (C178) [106]; caboxamycin (C190) [115]; and piperazimycin B (C191) [116]. Besides Streptomyces, other bacteria have also been explored. The bioactive fraction of Actinoalloateichus sp. exhibited a broad spectrum of anti-candidal activity. Further structural characterization identified caerulomycin A (C179) as an active metabolite, with MIC values of 0.78–1.56 μg/mL against fluconazole-resistant C. albicans, 0.39–0.78 μg/mL against C. glabrata, and 0.78–1.56 μg/mL against C. krusei [107]. An Arctic-sediment-derived actinomycete, Nocardia dassonvillei, produces extracellular substances rich in the secondary metabolite N-(2-hydroxyphenyl)-2-phenazinamine (C182), which showed antifungal activity against C. albicans, with a MIC value of 64 µg/mL [110].

2.4.2. Other Bacteria

High-throughput screening approaches have been routinely used to explore the secondary metabolites from many other marine bacteria with biological activity, as presented in Table 5. Examples include cycloprodigiosin (C192) (Pseudoalteromonas rubra), bulbimidazoles A−C (C193–C195) (Microbulbifer sp. DC3-6), and indolepyrazines A (C196) and B (C197) (Acinetobacter sp. ZZ1275), which were able to modify the susceptibility of C. albicans to antifungal drugs [123,124,125]. Recently, janthinopolyenemycins A (C198) and B (C199) (Janthinobacterium spp. ZZ145 and ZZ148) exhibited strong antifungal activity against C. albicans by expressing low MIC values [126]. The fermented broth of marine bacteria Bacillus licheniformis 09IDYM23 presented two anti-candidal glycolipids, ieodoglucomide C (C200) and ieodoglycolipid (C201), that also had activity against C. albicans [127]. Forazoline A (C202) and B (C203), derived from marine-invertebrate-associated bacteria, reduced the fungal burden level in mice infected with C. albicans [128]. Finally, the ethyl acetate extract of Bacillus subtilis yielded seven compounds, and all of them exhibited reasonable anti-candidal activity against C. albicans [129].

2.5. Fungi

The natural products produced by marine fungi can be classified into several groups, including alkaloids, polyketides, terpenoids, peptides, and phenolics, among others. Some of the most interesting natural products from marine fungi include cytotoxic compounds, with potential anticancer activity; immunomodulatory compounds, with potential applications in autoimmune diseases; and antimicrobial compounds, with potential applications in combating drug-resistant pathogens. The discovery of natural products from marine fungi is a rapidly growing field of research, as scientists continue to explore the vast and largely unexplored marine environment. The potential of these natural products to serve as lead compounds for drug discovery has generated significant interest, with several marine-derived compounds already in clinical trials. In addition, the sustainable production of natural products from marine fungi has the potential to provide a renewable source of bioactive compounds with minimal environmental impact. The detailed structures of some important natural products from marine fungi are presented in Figure 5 and Table 6.

2.5.1. Penicillium spp.

Penicillium is a genus of fungi that includes several species known for their ability to produce a wide range of bioactive compounds, and it is the source of the first antibiotic, penicillin [157,158,159]. In particular, marine Penicillium species have gained increasing attention in recent years due to their unique properties to produce novel bioactive compounds [160]. They are found in various marine habitats, including sediments, mangroves, coral reefs, and seawater. A considerable number of studies have provided evidence of the bioactivity of compounds from Penicillium fungi; however, only few studies highlighted the importance of antifungal therapy. Here, some of the compounds with antifungal properties are reported. For example, pyrrospirones C-I (C249–C255) (Penicillium sp. ZZ380) are an uncommon class of alkaloids that inhibited the growth of C. albicans [147]. Melearoride A (C260) and B (C266) from Penicillium meleagrinum var. viridiflavum had activity against C. albicans and synergistic interaction with fluconazole against azole-resistant C. albicans [150]. Similar research was conducted by Kaleem et al. (2020), which resulted in the identification of 16 compounds, including andrastones B (C277) and C (C278), that had greater anti-candidal action [161].

2.5.2. Endophytic Fungi

Amongst endophytic fungi, Cladosporium sp. was found to have two isolated compounds with biological activity: sporiolides A (C274) exhibited strong activity against C. albicans, with a concentration of 16.7 µg/mL, and sporiolides B (C275) showed moderate cytotoxicity against murine lymphoma L1210 cells [155]. Endophytic Aspergillus niger EN-13 produced nigerasperone C (C256), with moderate activity against C. albicans [148]. Furthermore, biologically active molecules didymellamide A (C272) and B-D (C279–C281) (Stagonosporopsis cucurbitacearum), as well as pleosporallin D (C267) and E (C268) (Pleosporales sp.), were obtained from different endophytic marine fungi with activity against C. albicans [151,153]. Aspergillus sp. is associated with sponge-produced tetrahydrofuran derivative known as aspericacid B (C282) but it exhibited no activity towards Candida. An another study reported that terretrione C (C237) from tunicate-derived fungus, Penicillium sp. CYE-87 was active against C. albicans with the MIC of 32 µg/mL [143]. Sponge-derived endophytic fungus Fusarium sp. LY019 yielded two alkaloids, fusaripyridines A (C283) and B (C284), that were identified as inhibitors of C. albicans growth, but they were not active against certain bacteria and HeLa cells [162]. Other promising antifungal compounds against C. albicans are the new thiodiketopiperazine (C285), epipolythiodiketopiperazine (C286), and trichothecene (C287) derivatives from Aspergillus terreus and Trichoderma cf. brevicompactum, respectively [140,141].

2.5.3. Other Fungi

Recently, several new metabolites such as talaromydien A (C288) and talaroisocoumarin A (C231) were isolated from Talaromyces sp. ZZ1616. Talaroisocoumarin A (C231) expressed superior activity against C. albicans (26 µg/mL) and some bacterial species [139]. Furthermore, bioactive compounds of Aspergillus fumigatus were effective against C. albicans with a MIC of >100 µM [163]. Similar observations were made by Ding et al. and Huang et al. (2018), who proved the efficacy of secondary metabolites against C. albicans obtained from Aspergillus versicolor and Cladosporium sp. SCSIO z0025, respectively [144,145]. Ditalaromylectones A (C227) and B (C289), along with seven known compounds, were isolated from Talaromyces mangshanicus BTBU20211089, but only ditalaromylectone A (C227) was active against C. albicans [136]. Ent-epiheveadride (C229), a new nonadride enantiomer isolated from the marine fungus Aspergillus chevalieri PSU-AMF79, had moderate inhibitory activity against C. albicans with a MIC value of 200 µg/mL [137].

2.6. Miscellaneous

The marine sources of antifungal compounds are not limited to sponges, algae, sea cucumbers, bacteria, and fungi, but there are some other important sources from the marine environment, such as corals, mollusks, coelenterates, and bryozoans. For example, iseolide A (C241) (isolated from coral-derived actinomycete Streptomyces sp.) [94] and nocarimidazoles C (C290) and D (C291) (isolated from coral-derived actinomycete Kocuria sp.) [164,165] demonstrated activity against C. albicans. Polyketides are unique structures isolated from dinoflagellate Amphidinium carterae, with proven antifungal activity [166]. Similarly, Didemnum sp. collected from the Red Sea produce didemnaketals F (C292) and G (C293), which were able to control the growth of C. albicans at a concentration of 100 µg/disc with a zone of inhibition of 16–24 mm [167]. Apart from this, several studies reported some compounds with potential antifungal action from marine snail Cenchritis muricatus [168], sea squirt Ciona intestinalis [169], tunicate Halocynthia aurantium [170], ascidian Clavelina oblonga [171], and tunicate Eudistoma sp. [172].

3. Discussion and Future Perspectives

In this review, among the data collected from different studies focused on marine organisms, sponges, algae, bacteria, and fungi seem to be the major contributors of bioactive compounds with anti-candidal activity. Promisingly, marine sponges stand out due to having a large number of biologically important molecules [24]. In particular, sponges have been recognized as prolific producers of alkaloids, terpenoids, peptides, polyketides, and sterols, among others [31,32,33,36,37,38,42,44,48,49,50,51,55,56]. All these classes of molecules exhibit significant biological activities against Candida species [24,25,26,27,28,43,47,54].
Although natural products from sponges and other marine organisms are well known for their antifungal activities [173], many concerns still remain over their other features, including structural complexity, supply and availability, standardization and quality control, possible drug–drug interactions, side effects, toxicity, and lack of clinical evidence [11]. Among them, supply chain management is the primary concern because extracting a single molecule from a complex mixture is a long and thorough process.
To overcome the supply chain management, great attention has been given to in situ cultivation and aquaculture [11]. By adopting these methods, researchers can stimulate appropriate culture conditions without disrupting biodiversity, providing access to diverse sources of raw materials for a constant supply. In addition, both methods contribute to the standardized production of raw materials, facilitating the processes involved in the research and development of marine products.
An understanding of the complex structure of bioactive compounds can also provide insights into the production of similar kinds of chemical compounds. Chemical synthesis through which natural products are reproduced from different sources offers the option to obtain a product with comparably lesser cost than a product originating from its source [12,16,17].
We expect that this review can prompt researchers to establish biobanks and sample repositories of marine products with antifungal activities, promoting international collaborations and advances for the future application of marine natural products on Candida infections.

4. Conclusions

The need for new anti-candidal compounds has increased due to the emergence of various drug-resistant isolates; meanwhile, knowledge of different ecosystems can provide insights into drug discovery. The marine environment is being recognized as the treasure trove of novel chemical cues, whose potency, detailed structures, and functional properties still need to be explored as they are in terrestrial sources.
In summary, we found that sponges, algae, and microorganisms have been the major marine sources employed to extract metabolites with potential antifungal action, although many other organisms can also provide important sources of antifungal activity. According to the studies reported, a wide number of natural compounds from the marine environment were found to be effective against clinical and reference strains of C. albicans and non-albicans species, including C. auris, a multi-drug-resistant species. Several compounds showed stronger antifungal activity than conventional antifungal drugs, such as fluconazole and amphotericin B. Interestingly, some of these compounds had synergistic interaction with antifungal drugs and altered the resistance mechanisms, making the Candida cells more susceptible to fluconazole and echinocandins. In addition to antifungal activity, certain compounds showed activity against bacteria and immunomodulatory effects, which can potentialize its effects in the treatment of candidiasis since this infection can be associated with the presence of bacteria and immunodeficiency.
Although many antifungal compounds had already been isolated from marine organisms, most studies are limited to verifying their antifungal activity in in vitro models. To translate these compounds into clinical applications, there is still a long way to go, with the development of in vivo studies, toxicity assays, and investigations of action mechanisms. Moreover, some marine organisms are protected by international law in specific regions of the world, and it is uncertain whether there are enough raw materials to ensure a steady supply of natural products. Thus, new approaches are needed to address the issues related to the sustainable production and marketing of natural products using contemporary technologies to preserve maritime ecosystems.

Author Contributions

All authors have contributed equally. All authors have read and agreed to the published version of the manuscript.

Funding

Coordination Improvement of Higher Education Personnel (CAPES/Brazil): 88887.695977/2022-00; National Council for Scientific and Technological Development: (CNPq/Brazil): 310265/2022-3.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Azanza, J.R.; Grau, S.; Vázquez, L.; Rebollo, P.; Peral, C.; López-Ibáñez de Aldecoa, A.; López-Gómez, V. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain. Mycoses 2021, 64, 66–77. [Google Scholar] [CrossRef]
  2. Brown, G.D.; Denning, D.W.; Gow, N.A.R.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden Killers: Human Fungal Infections. Sci. Transl. Med. 2012, 4, 165. [Google Scholar] [CrossRef] [Green Version]
  3. Richardson, M.D. Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother. 2005, 56, i5–i11. [Google Scholar] [CrossRef] [Green Version]
  4. Fisher, M.C.; Gurr, S.J.; Cuomo, C.A.; Blehert, D.S.; Jin, H.; Stukenbrock, E.H.; Stajich, J.E.; Kahmann, R.; Boone, C.; Denning, D.W.; et al. Threats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture. mBio 2020, 11, e00449-20. [Google Scholar] [CrossRef] [PubMed]
  5. Ocansey, B.K.; Pesewu, G.A.; Codjoe, F.S.; Osei-Djarbeng, S.; Feglo, P.K.; Denning, D.W. Estimated Burden of Serious Fungal Infections in Ghana. J. Fungi 2019, 5, 38. [Google Scholar] [CrossRef] [Green Version]
  6. Gintjee, T.J.; Donnelley, M.A.; Thompson, G.R. Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. J. Fungi 2020, 6, 28. [Google Scholar] [CrossRef] [Green Version]
  7. Fuentefria, A.; Pippi, B.; Lana, D.D.; Donato, K.; de Andrade, S. Antifungals discovery: An insight into new strategies to combat antifungal resistance. Lett. Appl. Microbiol. 2018, 66, 2–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Morio, F.; Jensen, R.H.; Le Pape, P.; Arendrup, M.C. Molecular basis of antifungal drug resistance in yeasts. Int. J. Antimicrob. Agents 2017, 50, 599–606. [Google Scholar] [CrossRef] [PubMed]
  9. Lee, Y.; Puumala, E.; Robbins, N.; Cowen, L.E. Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond. Chem. Rev. 2020, 121, 3390–3411. [Google Scholar] [CrossRef]
  10. Kołaczkowska, A.; Kołaczkowski, M. Drug resistance mechanisms and their regulation in non-albicans Candida species. J. Antimicrob. Chemother. 2016, 71, 1438–1450. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Atanasov, A.G.; Zotchev, S.B.; Dirsch, V.M.; Supuran, C.T. Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug Discov. 2021, 20, 200–216. [Google Scholar] [CrossRef] [PubMed]
  12. König, G.M.; Kehraus, S.; Seibert, S.F.; Abdel-Lateff, A.; Müller, D. Natural products from marine organisms and their asso-ciated microbes. ChemBioChem 2006, 7, 229–238. [Google Scholar] [CrossRef] [PubMed]
  13. Calixto, J.B. The role of natural products in modern drug discovery. An. Acad. Bras. Ciênc. 2019, 91, e20190105. [Google Scholar] [CrossRef] [PubMed]
  14. Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2019, 36, 122–173. [Google Scholar] [CrossRef] [Green Version]
  15. Khalifa, S.A.M.; Elias, N.; Farag, M.A.; Chen, L.; Saeed, A.; Hegazy, M.-E.F.; Moustafa, M.S.; El-Wahed, A.A.; Al-Mousawi, S.M.; Musharraf, S.G.; et al. Marine Natural Products: A Source of Novel Anticancer Drugs. Mar. Drugs 2019, 17, 491. [Google Scholar] [CrossRef] [Green Version]
  16. Gandhi, S.G.; Mahajan, V.; Bedi, Y.S. Changing trends in biotechnology of secondary metabolism in medicinal and aromatic plants. Planta 2014, 241, 303–317. [Google Scholar] [CrossRef]
  17. Shahnawaz, M. (Ed.) Biotechnological Approaches to Enhance Plant Secondary Metabolites: Recent Trends and Future Pro-spects; CRC Press: Boca Raton, FL, USA, 2022. [Google Scholar]
  18. Marine Pharmacology. Mysite. Available online: https://www.marinepharmacology.org/ (accessed on 10 July 2023).
  19. Nieto, F.R.; Cobos, E.J.; Tejada, M.; Sánchez-Fernández, C.; González-Cano, R.; Cendán, C.M. Tetrodotoxin (TTX) as a Therapeutic Agent for Pain. Mar. Drugs 2012, 10, 281–305. [Google Scholar] [CrossRef]
  20. Martinez, M.A. Plitidepsin: A Repurposed Drug for the Treatment of COVID-19. Antimicrob. Agents Chemother. 2021, 65. [Google Scholar] [CrossRef]
  21. Bal, S.; Landau, H. AL amyloidosis: Untangling new therapies. Hematology 2021, 2021, 682–688. [Google Scholar] [CrossRef]
  22. Thompson, R.E.; Tuchman, A.J.; Alkon, D.L. Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Base-line for Advanced Alzheimer’s Disease in the Absence of Memantine. J. Alzheimer’s Dis. 2022, 86, 1221–1229. [Google Scholar] [CrossRef]
  23. Cai, Y.; Xu, W.; Gu, C.; Cai, X.; Qu, D.; Lu, L.; Xie, Y.; Jiang, S. Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. Virol Sin. 2020, 35, 857–860. [Google Scholar] [CrossRef] [PubMed]
  24. Anjum, K.; Abbas, S.Q.; Shah, S.A.A.; Akhter, N.; Batool, S.; Hassan, S.S.U. Marine Sponges as a Drug Treasure. Biomol. Ther. 2016, 24, 347–362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Thomas, T.R.A.; Kavlekar, D.P.; LokaBharathi, P.A. Marine Drugs from Sponge-Microbe Association—A Review. Mar. Drugs 2010, 8, 1417–1468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Hertiani, T.; Edrada-Ebel, R.; Ortlepp, S.; van Soest, R.W.; de Voogd, N.J.; Wray, V.; Hentschel, U.; Kozytska, S.; Müller, W.E.; Proksch, P. From anti-fouling to biofilm inhibition: New cytotoxic secondary metabolites from two Indonesian Agelas sponges. Bioorganic Med. Chem. 2010, 18, 1297–1311. [Google Scholar] [CrossRef]
  27. Dalisay, D.S.; Rogers, E.W.; Molinski, T.F. Oceanapiside, a marine natural product, targets the sphingolipid pathway of flu-conazole-resistant Candida glabrata. Mar. Drugs 2021, 19, 126. [Google Scholar] [CrossRef]
  28. Makarieva, T.N.; Ivanchina, N.V.; Dmitrenok, P.S.; Guzii, A.G.; Stonik, V.A.; Dalisay, D.S.; Molinski, T.F. Oceanalin B, a Hybrid α, ω-Bifunctionalized Sphingoid Tetrahydroisoquinoline β-Glycoside from the Marine Sponge Oceanapia sp. Mar. Drugs 2021, 19, 635. [Google Scholar] [CrossRef]
  29. Ahirwar, A.; Kesharwani, K.; Deka, R.; Muthukumar, S.; Khan, M.J.; Rai, A.; Vinayak, V.; Varjani, S.; Joshi, K.B.; Morjaria, S. Microalgal drugs: A promising therapeutic reserve for the future. J. Biotechnol. 2022, 349, 32–46. [Google Scholar] [CrossRef]
  30. DiGirolamo, J.A.; Li, X.-C.; Jacob, M.R.; Clark, A.M.; Ferreira, D. Reversal of Fluconazole Resistance by Sulfated Sterols from the Marine Sponge Topsentia sp. J. Nat. Prod. 2009, 72, 1524–1528. [Google Scholar] [CrossRef] [Green Version]
  31. Kubota, T.; Iwai, T.; Takahashi-Nakaguchi, A.; Fromont, J.; Gonoi, T.; Kobayashi, J. Agelasines O–U, new diterpene alkaloids with a 9-N-methyladenine unit from a marine sponge Agelas sp. Tetrahedron 2012, 68, 9738–9744. [Google Scholar] [CrossRef]
  32. Chu, M.-J.; Tang, X.-L.; Qin, G.-F.; Sun, Y.-T.; Li, L.; de Voogd, N.J.; Li, P.-L.; Li, G.-Q. Pyrrole Derivatives and Diterpene Alkaloids from the South China Sea Sponge Agelas nakamurai. Chem. Biodivers. 2017, 14, e1600446. [Google Scholar] [CrossRef]
  33. Youssef, D.T.A.; Shaala, L.A.; Alshali, K.Z. Bioactive Hydantoin Alkaloids from the Red Sea Marine Sponge Hemimycale arabica. Mar. Drugs 2015, 13, 6609–6619. [Google Scholar] [CrossRef] [Green Version]
  34. Jamison, M.T.; Molinski, T.F. Antipodal crambescin A2 homologues from the marine sponge Pseudaxinella reticulata. Anti-fungal structure–activity relationships. J. Nat. Prod. 2015, 78, 557–561. [Google Scholar] [CrossRef] [PubMed]
  35. Youssef, D.T.; Shaala, L.A.; Mohamed, G.A.; Badr, J.M.; Bamanie, F.H.; Ibrahim, S.R. Theonellamide G, a potent antifungal and cytotoxic bicyclic glycopeptide from the Red Sea marine sponge Theonella swinhoei. Mar. Drugs 2014, 12, 1911–1923. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Lee, S.-H.; Jeon, J.-E.; Ahn, C.-H.; Chung, S.-C.; Shin, J.; Oh, K.-B. Inhibition of yeast-to-hypha transition in Candida albicans by phorbasin H isolated from Phorbas sp. Appl. Microbiol. Biotechnol. 2012, 97, 3141–3148. [Google Scholar] [CrossRef]
  37. Tanaka, N.; Kusama, T.; Takahashi-Nakaguchi, A.; Gonoi, T.; Fromont, J.; Kobayashi, J. Nagelamides U–W, bromopyrrole alkaloids from a marine sponge Agelas sp. Tetrahedron Lett. 2013, 54, 3794–3796. [Google Scholar] [CrossRef]
  38. Tanaka, N.; Kusama, T.; Takahashi-Nakaguchi, A.; Gonoi, T.; Fromont, J.; Kobayashi, J.I. Nagelamides X–Z, dimeric bro-mopyrrole alkaloids from a marine sponge Agelas sp. Org. Lett. 2013, 15, 3262–3265. [Google Scholar] [CrossRef]
  39. Kumar, R.; Subramani, R.; Feussner, K.-D.; Aalbersberg, W. Aurantoside K, a New Antifungal Tetramic Acid Glycoside from a Fijian Marine Sponge of the Genus Melophlus. Mar. Drugs 2012, 10, 200–208. [Google Scholar] [CrossRef] [Green Version]
  40. Yu, H.-B.; Liu, X.-F.; Xu, Y.; Gan, J.-H.; Jiao, W.-H.; Shen, Y.; Lin, H.-W. Woodylides A–C, New Cytotoxic Linear Polyketides from the South China Sea Sponge Plakortis simplex. Mar. Drugs 2012, 10, 1027–1036. [Google Scholar] [CrossRef] [PubMed]
  41. Angawi, R.F.; Bavestrello, G.; Calcinai, B.; Dien, H.A.; Donnarumma, G.; Tufano, M.A.; Paoletti, I.; Grimaldi, E.; Chianese, G.; Fattorusso, E.; et al. Aurantoside J: A new tetramic acid glycoside from Theonella swinhoei. Insights into the antifungal potential of aurantosides. Mar. Drugs 2011, 9, 2809–2817. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Kon, Y.; Kubota, T.; Shibazaki, A.; Gonoi, T.; Kobayashi, J.I. Ceratinadins A–C, new bromotyrosine alkaloids from an Oki-nawan marine sponge Pseudoceratina sp. Bioorganic Med. Chem. Lett. 2010, 20, 4569–4572. [Google Scholar] [CrossRef]
  43. Makarieva, T.N.; Denisenko, V.A.; Dmitrenok, P.S.; Guzii, A.G.; Santalova, E.A.; Stonik, V.A.; Molinski, T.F. Oceanalin A, a hybrid α, ω-bifunctionalized sphingoid tetrahydroisoquinoline β-glycoside from the marine sponge Oceanapia sp. Org. Lett. 2005, 7, 2897–2900. [Google Scholar] [CrossRef] [PubMed]
  44. Sionov, E.; Roth, D.; Sandovsky-Losica, H.; Kashman, Y.; Rudi, A.; Chill, L.; Berdicevsky, I.; Segal, E. Antifungal effect and possible mode of activity of a compound from the marine sponge Dysidea herbacea. J. Infect. 2005, 50, 453–460. [Google Scholar] [CrossRef] [PubMed]
  45. Jacob, M.R.; Hossain, C.F.; Mohammed, K.A.; Smillie, T.J.; Clark, A.M.; Walker, L.A.; Nagle, D.G. Reversal of Fluconazole Resistance in Multidrug Efflux-Resistant Fungi by the Dysidea a renaria Sponge Sterol 9α, 11α-Epoxycholest-7-ene-3β, 5α, 6α, 19-tetrol 6-Acetate. J. Nat. Prod. 2003, 66, 1618–1622. [Google Scholar] [CrossRef]
  46. Fernández, R.; Dherbomez, M.; Letourneux, Y.; Nabil, M.; Verbist, J.F.; Biard, J.F. Antifungal metabolites from the marine sponge Pachastrissa sp.: New bengamide and bengazole derivatives. J. Nat. Prod. 1999, 62, 678–680. [Google Scholar] [CrossRef]
  47. Sata, N.U.; Matsunaga, S.; Fusetani, N.; van Soest, R.W. Aurantosides D, E, and F: New Antifungal Tetramic Acid Glycosides from the Marine Sponge Siliquariaspongiajaponica. J. Nat. Prod. 1999, 62, 969–971. [Google Scholar] [CrossRef]
  48. Schmidt, E.W.; Faulkner, D.J. Microsclerodermins C–E, antifungal cyclic peptides from the lithistid marine sponges Theonella sp. and Microscleroderma sp. Tetrahedron 1998, 54, 3043–3056. [Google Scholar] [CrossRef]
  49. Clark, D.P.; Carroll, J.; Naylor, S.; Crews, P. An antifungal cyclodepsipeptide, cyclolithistide A, from the sponge Theonella swinhoei. J. Org. Chem. 1998, 63, 8757–8764. [Google Scholar] [CrossRef]
  50. Searle, P.A.; Molinski, T.F. Phorboxazoles A and B: Potent cytostatic macrolides from marine sponge Phorbas species. J. Am. Chem. Soc. 1995, 117, 8126–8131. [Google Scholar] [CrossRef]
  51. Bewley, C.A.; Faulkner, D.J. Theonegramide, an Antifungal Glycopeptide from the Philippine Lithistid Sponge Theonella swinhoei. J. Org. Chem. 1994, 59, 4849–4852. [Google Scholar] [CrossRef]
  52. Matsunaga, S.; Fusetani, N.; Hashimoto, K.; Walchli, M.; Theonellamide, F. A novel antifungal bicyclic peptide from a marine sponge Theonella sp. J. Am. Chem. Soc. 1989, 111, 2582–2588. [Google Scholar] [CrossRef]
  53. Kernan, M.R.; Molinski, T.F.; Faulkner, D.J. Macrocyclic antifungal metabolites from the Spanish dancer nudibranch Hexa-branchus sanguineus and sponges of the genus Halichondria. J. Org. Chem. 1988, 53, 5014–5020. [Google Scholar] [CrossRef]
  54. Nicholas, G.M.; Li, R.; MacMillan, J.B.; Molinski, T.F. Antifungal activity of bifunctional sphingolipids. intramolecular synergism within long-chain α,ω-bis-aminoalcohols. Bioorganic Med. Chem. Lett. 2002, 12, 2159–2162. [Google Scholar] [CrossRef] [PubMed]
  55. Zhu, Y.; Wang, Y.; Gu, B.-B.; Yang, F.; Jiao, W.-H.; Hu, G.-H.; Yu, H.-B.; Han, B.-N.; Zhang, W.; Shen, Y.; et al. Antifungal bromopyrrole alkaloids from the South China Sea sponge Agelas sp. Tetrahedron 2016, 72, 2964–2971. [Google Scholar] [CrossRef]
  56. Kubota, T.; Nakamura, K.; Kurimoto, S.I.; Sakai, K.; Fromont, J.; Gonoi, T.; Kobayashi, J.I. Zamamidine D, a manzamine alkaloid from an Okinawan Amphimedon sp. marine sponge. J. Nat. Prod. 2017, 80, 1196–1199. [Google Scholar] [CrossRef]
  57. Gunasekera, S.P.; Pomponi, S.A.; McCarthy, P.J. Discobahamins A and B, New Peptides from the Bahamian Deep Water Marine Sponge Discodermia sp. J. Nat. Prod. 1994, 57, 79–83. [Google Scholar] [CrossRef] [PubMed]
  58. Said, A.A.E.; Mahmoud, B.K.; Attia, E.Z.; Abdelmohsen, U.R.; Fouad, M.A. Bioactive natural products from marine sponges belonging to family Hymedesmiidae. RSC Adv. 2021, 11, 16179–16191. [Google Scholar] [CrossRef]
  59. Tripathi, S.K.; Feng, Q.; Liu, L.; Levin, D.E.; Roy, K.K.; Doerksen, R.J.; Baerson, S.R.; Shi, X.; Pan, X.; Xu, W.-H.; et al. Puupehenone, a Marine-Sponge-Derived Sesquiterpene Quinone, Potentiates the Antifungal Drug Caspofungin by Disrupting Hsp90 Activity and the Cell Wall Integrity Pathway. Msphere 2020, 5. [Google Scholar] [CrossRef] [Green Version]
  60. Jang, J.-H.; van Soest, R.W.M.; Fusetani, N.; Matsunaga, S. Pseudoceratins A (Ia) and B (Ib), Antifungal Bicyclic Bromotyrosine-Derived Metabolites from the Marine Sponge Pseudoceratina purpurea. Cheminform 2007, 38. [Google Scholar] [CrossRef]
  61. Chen, M.; Yan, Y.; Ge, H.; Jiao, W.H.; Zhang, Z.; Lin, H.W. Pseudoceroximes A–E and Pseudocerolides A–E, Bromotyrosine Derivatives from a Pseudoceratina sp. Marine Sponge Collected in the South China Sea. Eur. J. Org. Chem. 2020, 17, 2583–2591. [Google Scholar] [CrossRef]
  62. Shin, J.; Lee, H.S.; Kim, J.Y.; Shin, H.J.; Ahn, J.W.; Paul, V.J. New Macrolides from the Sponge Chondrosia c orticata. J. Nat. Prod. 2004, 67, 1889–1892. [Google Scholar] [CrossRef]
  63. Nabeta, H.W.; Kouokam, J.C.; Lasnik, A.B.; Fuqua, J.L.; Palmer, K.E. Novel Antifungal Activity of Q-Griffithsin, a Broad-Spectrum Antiviral Lectin. Microbiol. Spectr. 2021, 9, e0095721. [Google Scholar] [CrossRef] [PubMed]
  64. Nabeta, H.W.; Lasnik, A.B.; Fuqua, J.L.; Wang, L.; Rohan, L.C.; Palmer, K.E. Antiviral lectin Q-Griffithsin suppresses fungal infection in murine models of vaginal candidiasis. Front. Cell. Infect. Microbiol. 2022, 12, 976033. [Google Scholar] [CrossRef] [PubMed]
  65. Ganeshkumar, A.; Suvaithenamudhan, S.; Elanthamilan, E.; Arun, G.; Dileepan, G.A.B.; Prabhusaran, N.; Rajaram, R. New insight of red seaweed derived Callophycin A as an alternative strategy to treat drug resistance vaginal candidiasis. Bioorganic Chem. 2020, 104, 104256. [Google Scholar] [CrossRef]
  66. Ji, N.Y.; Li, X.M.; Li, K.; Ding, L.P.; Gloer, J.B.; Wang, B.G. Diterpenes, sesquiterpenes, and a C15-acetogenin from the marine red alga Laurencia mariannensis. J. Nat. Prod. 2007, 70, 1901–1905. [Google Scholar] [CrossRef]
  67. Ganesan, R. Recovery of Aliphatic Fatty Acids from Red Seaweed Champia parvula (C. Agardh) and Its Antifungal Action. J. Aquat. Food Prod. Technol. 2019, 28, 922–932. [Google Scholar]
  68. Feng, M.-T.; Yu, X.-Q.; Yang, P.; Yang, H.; Lin, K.; Mao, S.-C. Two New Antifungal Polyunsaturated Fatty Acid Ethyl Esters from the Red Alga Laurencia okamurai. Chem. Nat. Compd. 2015, 51, 418–422. [Google Scholar] [CrossRef]
  69. Greff, S.; Zubia, M.; Genta-Jouve, G.; Massi, L.; Perez, T.; Thomas, O.P. Mahorones, highly brominated cyclopentenones from the red alga Asparagopsis taxiformis. J. Nat. Prod. 2014, 77, 1150–1155. [Google Scholar] [CrossRef] [Green Version]
  70. Yu, X.-Q.; He, W.-F.; Liu, D.-Q.; Feng, M.-T.; Fang, Y.; Wang, B.; Feng, L.-H.; Guo, Y.-W.; Mao, S.-C. A seco -laurane sesquiterpene and related laurane derivatives from the red alga Laurencia okamurai Yamada. Phytochemistry 2014, 103, 162–170. [Google Scholar] [CrossRef] [PubMed]
  71. Lopes, G.; Pinto, E.; Andrade, P.B.; Valentao, P. Antifungal activity of phlorotannins against dermatophytes and yeasts: Ap-proaches to the mechanism of action and influence on Candida albicans virulence factor. PLoS ONE 2013, 8, e72203. [Google Scholar] [CrossRef]
  72. Liu, A.-H.; Liu, D.-Q.; Liang, T.-J.; Yu, X.-Q.; Feng, M.-T.; Yao, L.-G.; Fang, Y.; Wang, B.; Feng, L.-H.; Zhang, M.-X.; et al. Caulerprenylols A and B, two rare antifungal prenylated para-xylenes from the green alga Caulerpa racemosa. Bioorganic Med. Chem. Lett. 2013, 23, 2491–2494. [Google Scholar] [CrossRef]
  73. Lin, A.S.; Stout, E.P.; Prudhomme, J.; Roch, K.L.; Fairchild, C.R.; Franzblau, S.G.; Kubanek, J. Bioactive Bromophycolides R− U from the Fijian red alga Callophycus serratus. J. Nat. Prod. 2010, 73, 275–278. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Alarif, W.M.; Al-Lihaibi, S.S.; Ayyad, S.-E.N.; Abdel-Rhman, M.H.; Badria, F.A. Laurene-type sesquiterpenes from the Red Sea red alga Laurencia obtusa as potential antitumor–antimicrobial agents. Eur. J. Med. Chem. 2012, 55, 462–466. [Google Scholar] [CrossRef] [PubMed]
  75. Xu, X.; Piggott, A.M.; Yin, L.; Capon, R.J.; Song, F. Symphyocladins A–G: Bromophenol adducts from a Chinese marine red alga, Symphyocladia latiuscula. Tetrahedron Lett. 2012, 53, 2103–2106. [Google Scholar] [CrossRef]
  76. Oh, K.-B.; Lee, J.H.; Chung, S.-C.; Shin, J.; Shin, H.J.; Kim, H.-K.; Lee, H.-S. Antimicrobial activities of the bromophenols from the red alga Odonthalia corymbifera and some synthetic derivatives. Bioorganic Med. Chem. Lett. 2008, 18, 104–108. [Google Scholar] [CrossRef] [PubMed]
  77. Li, X.C.; Jacob, M.R.; Ding, Y.; Agarwal, A.K.; Smillie, T.J.; Khan, S.I.; Clark, A.M. Capisterones A and B, which enhance fluconazole activity in Saccharomyces cerevisiae, from the marine green alga Penicillus capitatus. J. Nat. Prod. 2006, 69, 542–546. [Google Scholar] [CrossRef] [Green Version]
  78. Ankisetty, S.; Nandiraju, S.; Win, H.; Park, Y.C.; Amsler, C.D.; McClintock, J.B.; Baker, J.A.; Diyabalanage, T.K.; Pasaribu, A.; Singh, M.P.; et al. Chemical Investigation of Predator-Deterred Macroalgae from the Antarctic Peninsula. J. Nat. Prod. 2004, 67, 1295–1302. [Google Scholar] [CrossRef]
  79. Yang, W.-S.; Qi, X.-R.; Xu, Q.-Z.; Yuan, C.-H.; Yi, Y.-H.; Tang, H.-F.; Shen, L.; Han, H. A new sulfated triterpene glycoside from the sea cucumber Colochirus quadrangularis, and evaluation of its antifungal, antitumor and immunomodulatory activities. Bioorganic Med. Chem. 2021, 41, 116188. [Google Scholar] [CrossRef]
  80. Elbandy, M.; Rho, J.R.; Afifi, R. Analysis of saponins as bioactive zoochemicals from the marine functional food sea cucumber Bohadschia cousteaui. Eur. Food Res. Technol. 2014, 238, 937–955. [Google Scholar] [CrossRef]
  81. Wang, X.-H.; Zou, Z.-R.; Yi, Y.-H.; Han, H.; Li, L.; Pan, M.-X. Variegatusides: New Non-Sulphated Triterpene Glycosides from the Sea Cucumber Stichopus variegates Semper. Mar. Drugs 2014, 12, 2004–2018. [Google Scholar] [CrossRef] [Green Version]
  82. Wang, Z.; Zhang, H.; Yuan, W.; Gong, W.; Tang, H.; Liu, B.; Krohn, K.; Li, L.; Yi, Y.; Zhang, W. Antifungal nortriterpene and triterpene glycosides from the sea cucumber Apostichopus japonicus Selenka. Food Chem. 2012, 132, 295–300. [Google Scholar] [CrossRef]
  83. Yuan, W.-H.; Yi, Y.-H.; Tan, R.-X.; Wang, Z.-L.; Sun, G.-Q.; Xue, M.; Zhang, H.-W.; Tang, H.-F. Antifungal Triterpene Glycosides from the Sea Cucumber Holothuria (Microthele) axiloga. Planta Medica 2009, 75, 647–653. [Google Scholar] [CrossRef] [PubMed]
  84. Yuan, W.-H.; Yi, Y.-H.; Tang, H.-F.; Liu, B.-S.; Wang, Z.-L.; Sun, G.-Q.; Zhang, W.; Li, L.; Sun, P. Antifungal Triterpene Glycosides from the Sea Cucumber Bohadschia marmorata. Planta Medica 2008, 75, 168–173. [Google Scholar] [CrossRef] [PubMed]
  85. Yuan, W.-H.; Yi, Y.-H.; Xue, M.; Zhang, H.-W.; LA, M.-P. Two Antifungal Active Triterpene Glycosides from Sea Cucumber Holothuria (Microthele) axiloga. Chin. J. Nat. Med. 2008, 6, 105–108. [Google Scholar] [CrossRef]
  86. Kumar, R.; Chaturvedi, A.K.; Shukla, P.K.; Lakshmi, V. Antifungal activity in triterpene glycosides from the sea cucumber Actinopyga lecanora. Bioorganic Med. Chem. Lett. 2007, 17, 4387–4391. [Google Scholar] [CrossRef] [PubMed]
  87. Hagström, A.; Pommier, T.; Rohwer, F.; Simu, K.; Stolte, W.; Svensson, D.; Zweifel, U.L. Use of 16S Ribosomal DNA for Delineation of Marine Bacterioplankton Species. Appl. Environ. Microbiol. 2002, 68, 3628–3633. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  88. Debbab, A.; Aly, A.H.; Lin, W.H.; Proksch, P. Bioactive Compounds from Marine Bacteria and Fungi. Microb. Biotechnol. 2010, 3, 544–563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Dhakal, D.; Pokhrel, A.R.; Shrestha, B.; Maharjan, J.; Sohng, J.K. Streptomyces species: A promising source of antifungal metabolites. Appl. Microbiol. Biotechnol. 2020, 104, 2253–2264. [Google Scholar]
  90. Solanki, R.; Khanna, M.; Lal, R. Bioactive compounds from marine actinomycetes. Indian J. Microbiol. 2008, 48, 410–431. [Google Scholar] [CrossRef] [Green Version]
  91. El-Tarabily, K.A.; Nassar, A.H.; Sivasithamparam, K. Soil Actinomycetes and Their Metabolites for Control of Plant Fungal Pathogens. In Microbial Metabolites in Sustainable Agroecosystem; Springer: Singapore, 2020; pp. 279–310. [Google Scholar]
  92. Bao, Y.; Li, H.; Dong, Y.; Duan, H.; Li, H.; Li, W. Genome-Guided Discovery of Antifungal Filipins from a Deep-Sea-Derived Streptomyces antibioticus. J. Nat. Prod. 2022, 85, 365–374. [Google Scholar] [CrossRef]
  93. Li, W.; Ding, L.; Li, J.; Wen, H.; Liu, Y.; Tan, S.; Yan, X.; Shi, Y.; Lin, W.; Lin, H.-W.; et al. Novel Antimycin Analogues with Agricultural Antifungal Activities from the Sponge-Associated Actinomycete Streptomyces sp. NBU3104. J. Agric. Food Chem. 2022, 70, 8309–8316. [Google Scholar] [CrossRef]
  94. Zhang, Z.; Zhou, T.; Harunari, E.; Oku, N.; Igarashi, Y. Iseolides A–C, antifungal macrolides from a coral-derived actinomycete of the genus Streptomyces. J. Antibiot. 2020, 73, 534–541. [Google Scholar] [CrossRef]
  95. Zhang, S.; Gui, C.; Shao, M.; Kumar, P.S.; Huang, H.; Ju, J. Antimicrobial tunicamycin derivatives from the deep sea-derived Streptomyces xinghaiensis SCSIO S15077. Nat. Prod. Res. 2018, 34, 1499–1504. [Google Scholar] [CrossRef]
  96. Harunari, E.; Imada, C.; Igarashi, Y. Konamycins A and B and Rubromycins CA1 and CA2, Aromatic Polyketides from the Tunicate-Derived Streptomyces hyaluromycini MB-PO13T. J. Nat. Prod. 2019, 82, 1609–1615. [Google Scholar] [CrossRef]
  97. Pérez-Victoria, I.; Oves-Costales, D.; Lacret, R.; Martín, J.; Sánchez-Hidalgo, M.; Díaz, C.; Reyes, F. Structure elucidation and biosynthetic gene cluster analysis of caniferolides A–D, new bioactive 36-membered macrolides from the marine-derived Streptomyces caniferus CA-271066. Org. Biomol. Chem. 2019, 17, 2954–2971. [Google Scholar] [CrossRef] [PubMed]
  98. Pan, J.M.; Chen, H.Q.; Wang, H.; Yang, L.; Cai, C.H.; Mi, C.N.; Mei, W.L. New antifungal cycloheximide epimers pro-duced by Streptomyces sp. YG7. J. Asian Nat. Prod. Res. 2019, 23, 110–116. [Google Scholar] [CrossRef] [PubMed]
  99. Zhou, B.; Huang, Y.; Zhang, H.-J.; Li, J.-Q.; Ding, W.-J. Nitricquinomycins A-C, uncommon naphthopyrrolediones from the Streptomyces sp. ZS-A45. Tetrahedron 2019, 75, 3958–3961. [Google Scholar] [CrossRef]
  100. Chen, M.; Chai, W.; Zhu, R.; Song, T.; Zhang, Z.; Lian, X.-Y. Streptopyrazinones A−D, rare metabolites from marine-derived Streptomyces sp. ZZ446. Tetrahedron 2018, 74, 2100–2106. [Google Scholar] [CrossRef]
  101. Jiang, Y.-J.; Zhang, D.-S.; Zhang, H.-J.; Li, J.-Q.; Ding, W.-J.; Xu, C.-D.; Ma, Z.-J. Medermycin-Type Naphthoquinones from the Marine-Derived Streptomyces sp. XMA39. J. Nat. Prod. 2018, 81, 2120–2124. [Google Scholar] [CrossRef]
  102. Wang, F.; Fu, S.N.; Bao, Y.X.; Yang, Y.; Shen, H.F.; Lin, B.R.; Zhou, G.X. Kitamycin C, a new antimycin-type antibiotic from Streptomyces antibioticus strain 200-09. Nat. Prod. Res. 2017, 31, 1819–1824. [Google Scholar] [CrossRef]
  103. Aksoy, S.; Uzel, A.; Bedir, E. Cytosine-type nucleosides from marine-derived Streptomyces rochei 06CM016. J. Antibiot. 2015, 69, 51–56. [Google Scholar] [CrossRef] [PubMed]
  104. Bae, M.; Kim, H.; Moon, K.; Nam, S.J.; Shin, J.; Oh, K.B.; Oh, D.C. Mohangamides A and B, new dilactone-tethered pseu-do-dimeric peptides inhibiting Candida albicans isocitrate lyase. Org. Lett. 2015, 17, 712–715. [Google Scholar] [CrossRef] [PubMed]
  105. Che, Q.; Li, T.; Liu, X.; Yao, T.; Li, J.; Gu, Q.; Li, D.; Li, W.; Zhu, T. Genome scanning inspired isolation of reedsmycins A–F, poly-ene-polyol macrolides from Streptomyces sp. CHQ-64. Rsc Adv. 2015, 5, 22777–22782. [Google Scholar] [CrossRef]
  106. Lacret, R.; Oves-Costales, D.; Gómez, C.; Díaz, C.; De la Cruz, M.; Pérez-Victoria, I.; Vicente, F.; Genilloud, O.; Reyes, F. New ikarugamycin deriv-atives with antifungal and antibacterial properties from Streptomyces zhaozhouensis. Mar. Drugs 2014, 13, 128–140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  107. Ambavane, V.; Tokdar, P.; Parab, R.; Sreekumar, E.S.; Mahajan, G.; Mishra, P.D.; D’souza, L.; Ranadive, P. Caerulomycin A—An Antifungal Compound Isolated from Marine Actinomycetes. Adv. Microbiol. 2014, 4, 567–578. [Google Scholar] [CrossRef]
  108. Moon, K.; Ahn, C.-H.; Shin, Y.; Won, T.H.; Ko, K.; Lee, S.K.; Oh, K.-B.; Shin, J.; Nam, S.-I.; Oh, D.-C. New Benzoxazine Secondary Metabolites from an Arctic Actinomycete. Mar. Drugs 2014, 12, 2526–2538. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  109. Kim, D.G.; Moon, K.; Kim, S.H.; Park, S.H.; Park, S.; Lee, S.K.; Oh, K.B.; Shin, J.H.; Oh, D.C. Bahamaolides A and B, antifungal polyene polyol macrolides from the marine actinomycete Streptomyces sp. J. Nat. Prod. 2012, 75, 959–967. [Google Scholar] [CrossRef]
  110. Kaneda, M.; Naid, T.; Kithara, T.; Nakamura, S.; Kitahara, T.; Nakamura, S. Carbazomycins G and H, novel carbazomycin-congeners containing a quinol molety. J. Antibiot. 1988, 45, 602–608. [Google Scholar] [CrossRef] [Green Version]
  111. Yuan, G.; Hong, K.; Lin, H.; She, Z.; Li, J. New Azalomycin F Analogs from Mangrove Streptomyces sp. 211726 with Activity against Microbes and Cancer Cells. Mar. Drugs 2013, 11, 817–829. [Google Scholar] [CrossRef] [Green Version]
  112. Xu, L.Y.; Quan, X.S.; Wang, C.; Sheng, H.F.; Zhou, G.X.; Lin, B.R.; Jiang, R.W.; Yao, X.S. Antimycins A 19 and A 20, two new anti-mycins produced by marine actinomycete Streptomyces antibioticus H74-18. J. Antibiot. 2011, 64, 661–665. [Google Scholar] [CrossRef] [Green Version]
  113. El-Gendy, M.M.A.; El-Bondkly, A.M.A. Production and genetic improvement of a novel antimycotic agent, Saadamycin, against Dermatophytes and other clinical fungi from Endophytic Streptomyces sp. Hedaya48. J. Ind. Microbiol. Biotechnol. 2010, 37, 831–841. [Google Scholar] [CrossRef]
  114. Han, Y.; Yang, B.; Zhang, F.; Miao, X.; Li, Z. Characterization of Antifungal Chitinase from Marine Streptomyces sp. DA11 Associated with South China Sea Sponge Craniella Australiensis. Mar. Biotechnol. 2008, 11, 132–140. [Google Scholar] [CrossRef] [PubMed]
  115. Hohmann, C.; Schneider, K.; Bruntner, C.; Irran, E.; Nicholson, G.; Bull, A.T.; Jones, A.L.; Brown, R.; Stach, J.E.M.; Goodfellow, M.; et al. Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces sp. NTK 937. J. Antibiot. 2009, 62, 99–104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  116. Shaaban, K.; Shaaban, M.; Facey, P.; Fotso, S.; Frauendorf, H.; Helmke, E.; Maier, A.; Fiebig, H.H.; Laatsch, H. Electrospray Ionization Mass Spectra of Piperazimycins A and B and γ-Butyrolactones from a Marine-derived Streptomyces sp. J. Antibiot. 2008, 61, 736–746. [Google Scholar] [CrossRef] [Green Version]
  117. Zhang, F.; Zhao, M.; Braun, D.R.; Ericksen, S.S.; Piotrowski, J.S.; Nelson, J.; Peng, J.; Ananiev, G.E.; Chanana, S.; Barns, K.; et al. A marine microbiome antifungal targets urgent-threat drug-resistant fungi. Science 2020, 370, 974–978. [Google Scholar] [CrossRef]
  118. Peltola, M.; Tauraite, D.; Kananen, E. Antifungal compounds from Streptomyces hygroscopicus and their synergistic effects with fluconazole. J. Antibiot. 2020, 73, 831–839. [Google Scholar]
  119. Li, Z.; Li, J.; Li, Y.; Li, Y.; Zhao, L.X. Production of Antifungal Metabolites by Streptomyces sp. Isolated from the Soil of Mawei Mountain. J. Agric. Sci. 2021, 13, 96–102. [Google Scholar]
  120. Malla, M.A.; Dubey, A.K.; Kumar, A.; Yadav, P. Streptomyces as a source of antifungal metabolites: A review. J. Appl. Microbiol. 2021, 131, 1549–1560. [Google Scholar]
  121. Chen, S.; Zhang, D.; Chen, M.; Zhang, Z.; Lian, X.-Y. A rare diketopiperazine glycoside from marine-sourced Streptomyces sp. ZZ446. Nat. Prod. Res. 2018, 34, 1046–1050. [Google Scholar] [CrossRef]
  122. Kumar, A.; Sørensen, J.L.; Hansen, F.T.; Arvas, M.; Syed, M.F.; Hassan, L.; Benz, J.P.; Record, E.; Henrissat, B.; Pöggeler, S.; et al. Genome Sequencing and analyses of Two Marine Fungi from the North Sea Unraveled a Plethora of Novel Biosynthetic Gene Clusters. Sci. Rep. 2018, 8, 10187. [Google Scholar] [CrossRef] [Green Version]
  123. Setiyono, E.; Adhiwibawa, M.A.S.; Indrawati, R.; Prihastyanti, M.N.U.; Shioi, Y.; Brotosudarmo, T.H.P. An Indonesian Marine Bacterium, Pseudoalteromonas rubra, Produces Antimicrobial Prodiginine Pigments. ACS Omega 2020, 5, 4626–4635. [Google Scholar] [CrossRef] [Green Version]
  124. Karim, M.R.U.; Harunari, E.; Oku, N.; Akasaka, K.; Igarashi, Y. Bulbimidazoles A–C, Antimicrobial and Cytotoxic Alkanoyl Imidazoles from a Marine Gammaproteobacterium Microbulbifer Species. J. Nat. Prod. 2020, 83, 1295–1299. [Google Scholar] [CrossRef]
  125. Anjum, K.; Kaleem, S.; Yi, W.; Zheng, G.; Lian, X.; Zhang, Z. Novel antimicrobial indolepyrazines A and B from the ma-rine-associated Acinetobacter sp. ZZ1275. Mar. Drugs 2019, 17, 89. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  126. Anjum, K.; Sadiq, I.; Chen, L.; Kaleem, S.; Li, X.-C.; Zhang, Z.; Lian, X.-Y. Novel antifungal janthinopolyenemycins A and B from a co-culture of marine-associated Janthinobacterium spp. ZZ145 and ZZ148. Tetrahedron Lett. 2018, 59, 3490–3494. [Google Scholar] [CrossRef]
  127. Tareq, F.S.; Lee, H.S.; Lee, Y.J.; Lee, J.S.; Shin, H.J. Ieodoglucomide C and ieodoglycolipid, new glycolipids from a ma-rine-derived bacterium Bacillus licheniformis 09IDYM23. Lipids 2015, 50, 513–519. [Google Scholar] [CrossRef] [PubMed]
  128. Wyche, T.P.; Piotrowski, J.S.; Hou, Y.; Braun, D.; Deshpande, R.; McIlwain, S.; Ong, I.M.; Myers, C.L.; Guzei, I.A.; Westler, W.M.; et al. Forazoline A: Marine-Derived Polyketide with Antifungal In Vivo Efficacy. Angew. Chem. Int. Ed. 2014, 53, 11583–11586. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  129. Tareq, F.S.; Kim, J.H.; Lee, M.A.; Lee, H.-S.; Lee, J.-S.; Lee, Y.-J.; Shin, H.J. Antimicrobial Gageomacrolactins Characterized from the Fermentation of the Marine-Derived Bacterium Bacillus subtilis under Optimum Growth Conditions. J. Agric. Food Chem. 2013, 61, 3428–3434. [Google Scholar] [CrossRef]
  130. Xu, Z.; Zhang, Y.; Fu, H.; Zhong, H.; Hong, K.; Zhu, W. Antifungal quinazolinones from marine-derived Bacillus cereus and their preparation. Bioorganic Med. Chem. Lett. 2011, 21, 4005–4007. [Google Scholar] [CrossRef]
  131. Kunze, B.; Böhlendorf, B.; Reichenbach, H.; Höfle, G. Pedein A and B: Production, Isolation, Structure Elucidation and Biological Properties of New Antifungal Cyclopeptides from Chondromyces pediculatus (Myxobacteria). J. Antibiot. 2008, 61, 18–26. [Google Scholar] [CrossRef] [Green Version]
  132. Al-Zereini, W.; Schuhmann, I.; Laatsch, H.; Helmke, E.; Anke, H. New Aromatic Nitro Compounds from Salegentibacter sp. T436, an Arctic Sea Ice Bacterium: Taxonomy, Fermentation, Isolation and Biological Activities. J. Antibiot. 2007, 60, 301–308. [Google Scholar] [CrossRef] [Green Version]
  133. Neuhof, T.; Schmieder, P.; Preussel, K.; Dieckmann, R.; Pham, H.; Bartl, F.; von Döhren, H. Hassallidin A, a glycosylated lipopeptide with antifungal activity from the cyanobacterium Hassallia sp. J. Nat. Prod. 2005, 68, 695–700. [Google Scholar] [CrossRef]
  134. Barsby, T.; Kelly, M.T.; Andersen, R.J. Tupuseleiamides and Basiliskamides, New Acyldipeptides and Antifungal Polyketides Produced in Culture by a Bacilluslaterosporus Isolate Obtained from a Tropical Marine Habitat. J. Nat. Prod. 2002, 65, 1447–1451. [Google Scholar] [CrossRef] [PubMed]
  135. MacMillan, J.B.; Ernst-Russell, M.A.; De Ropp, J.S.; Molinski, T.F. Lobocyclamides A−C, Lipopeptides from a Cryptic Cyano-bacterial Mat Containing Lyngbya confervoides. J. Org. Chem. 2002, 67, 8210–8215. [Google Scholar] [CrossRef]
  136. Zhang, K.; Zhang, X.; Lin, R.; Yang, H.; Song, F.; Xu, X.; Wang, L. New Secondary Metabolites from the Marine-Derived Fungus Talaromyces mangshanicus BTBU20211089. Mar. Drugs 2022, 20, 79. [Google Scholar] [CrossRef]
  137. Ningsih, B.N.S.; Rukachaisirikul, V.; Phongpaichit, S.; Preedanon, S.; Sakayaroj, J.; Muanprasat, C. A nonadride derivative from the marine-derived fungus Aspergillus chevalieri PSU-AMF79. Nat. Prod. Res. 2022, 37, 2311–2318. [Google Scholar] [CrossRef] [PubMed]
  138. Nuansri, S.; Rukachaisirikul, V.; Rungwirain, N.; Kaewin, S.; Yimnual, C.; Phongpaichit, S.; Preedanon, S.; Sakayaroj, J.; Muanprasat, C. α-Pyrone and decalin derivatives from the marine-derived fungus Trichoderma harzianum PSU-MF79. Nat. Prod. Res. 2021, 36, 5462–5469. [Google Scholar] [CrossRef] [PubMed]
  139. Ma, M.; Yi, W.; Qin, L.; Lian, X.-Y.; Zhang, Z. Talaromydien a and talaroisocoumarin A, new metabolites from the marine-sourced fungus Talaromyces sp. ZZ1616. Nat. Prod. Res. 2020, 36, 460–465. [Google Scholar] [CrossRef] [PubMed]
  140. Wu, J.-S.; Shi, X.-H.; Yao, G.-S.; Shao, C.-L.; Fu, X.-M.; Zhang, X.-L.; Guan, H.-S.; Wang, C.-Y. New Thiodiketopiperazine and 3,4-Dihydroisocoumarin Derivatives from the Marine-Derived Fungus Aspergillus terreus. Mar. Drugs 2020, 18, 132. [Google Scholar] [CrossRef] [Green Version]
  141. Yamazaki, H.; Takahashi, O.; Kirikoshi, R.; Yagi, A.; Ogasawara, T.; Bunya, Y.; Namikoshi, M. Epipolythiodiketopipera-zine and trichothecene derivatives from the NaI-containing fermentation of marine-derived Trichoderma cf. brevicompactum. J. Antibiot. 2020, 73, 559–567. [Google Scholar] [CrossRef]
  142. Yang, B.; He, Y.; Lin, S.; Zhang, J.; Li, H.; Wang, J.; Zhang, Y. Antimicrobial dolabellanes and atranones from a ma-rine-derived strain of the toxigenic fungus Stachybotrys chartarum. J. Nat. Prod. 2019, 82, 1923–1929. [Google Scholar] [CrossRef]
  143. Shaala, L.A.; Youssef, D.T. Identification and bioactivity of compounds from the fungus Penicillium sp. CYE-87 isolated from a marine tunicate. Mar. Drugs 2015, 13, 1698–1709. [Google Scholar] [CrossRef] [Green Version]
  144. Ding, L.; Xu, P.; Li, T.; Liao, X.; He, S.; Xu, S. Asperfurandiones A and B, two antifungal furandione analogs from a ma-rine-derived fungus Aspergillus versicolor. Nat. Prod. Res. 2019, 33, 3404–3408. [Google Scholar] [CrossRef] [PubMed]
  145. Huang, Z.-H.; Nong, X.-H.; Liang, X.; Qi, S.-H. New tetramic acid derivatives from the deep-sea-derived fungus Cladosporium sp. SCSIO z0025. Tetrahedron 2018, 74, 2620–2626. [Google Scholar] [CrossRef]
  146. Yu, H.-B.; Wang, X.-L.; Xu, W.-H.; Zhang, Y.-X.; Qian, Y.-S.; Zhang, J.-P.; Lu, X.-L.; Liu, X.-Y. Eutypellenoids A–C, New Pimarane Diterpenes from the Arctic Fungus Eutypella sp. D-1. Mar. Drugs 2018, 16, 284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  147. Song, T.; Chen, M.; Chai, W.; Zhang, Z.; Lian, X.Y. New bioactive pyrrospirones C− I from a marine-derived fungus Penicillium sp. ZZ380. Tetrahedron 2018, 74, 884–891. [Google Scholar] [CrossRef]
  148. Zhang, Y.; Li, X.M.; Wang, B.G. Nigerasperones A~C, new monomeric and dimeric naphtho-γ-pyrones from a marine al-ga-derived endophytic fungus Aspergillus niger EN-13. J. Antibiot. 2007, 60, 204–210. [Google Scholar] [CrossRef]
  149. Wang, J.; Yao, Q.-F.; Amin, M.; Nong, X.-H.; Zhang, X.-Y.; Qi, S.-H. Penicillenols from a deep-sea fungus Aspergillus restrictus inhibit Candida albicans biofilm formation and hyphal growth. J. Antibiot. 2017, 70, 763–770. [Google Scholar] [CrossRef]
  150. Okabe, M.; Sugita, T.; Kinoshita, K.; Koyama, K. Macrolides from a Marine-Derived Fungus, Penicillium meleagrinum var. viridiflavum, Showing Synergistic Effects with Fluconazole against Azole-Resistant Candida albicans. J. Nat. Prod. 2016, 79, 1208–1212. [Google Scholar] [CrossRef]
  151. Chen, C.J.; Zhou, Y.Q.; Liu, X.X.; Zhang, W.J.; Hu, S.S.; Lin, L.P.; Ge, H.M. Antimicrobial and anti-inflammatory com-pounds from a marine fungus Pleosporales sp. Tetrahedron Lett. 2015, 56, 6183–6189. [Google Scholar] [CrossRef]
  152. Xu, D.X.; Sun, P.; Kurtan, T.; Mandi, A.; Tang, H.; Liu, B.; Zhang, W. Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka. J. Nat. Prod. 2014, 77, 1179–1184. [Google Scholar] [CrossRef]
  153. Haga, A.; Tamoto, H.; Ishino, M.; Kimura, E.; Sugita, T.; Kinoshita, K.; Koyama, K. Pyridone alkaloids from a ma-rine-derived fungus, Stagonosporopsis cucurbitacearum, and their activities against azole-resistant Candida albicans. J. Nat. Prod. 2013, 76, 750–754. [Google Scholar] [CrossRef]
  154. Singh, S.B.; Zink, D.L.; Doss, G.A.; Polishook, J.D.; Ruby, C.; Register, E.; Kelly, T.M.; Bonfiglio, C.; Williamson, J.M.; Kelly, R. Citrafungins A and B, Two New Fungal Metabolite Inhibitors of GGTase I with Antifungal Activity. Org. Lett. 2004, 6, 337–340. [Google Scholar] [CrossRef]
  155. Shigemori, H.; Kasai, Y.; Komatsu, K.; Tsuda, M.; Mikami, Y.; Kobayashi, J. Sporiolides A and B, New Cytotoxic Twelve-Membered Macrolides from a Marine-Derived Fungus Cladosporium Species. Mar. Drugs 2004, 2, 164–169. [Google Scholar] [CrossRef] [Green Version]
  156. Edrada, R.A.; Heubes, M.; Brauers, G.; Wray, V.; Berg, A.; Gräfe, U.; Wohlfarth, M.; Mühlbacher, J.; Schaumann, K.; Bring-mann, G.; et al. Online analysis of xestodecalactones A-C, novel bioactive metabolites from the fungus Penicillium cf montanense and their subsequent isolation from the sponge Xestospongia exigua. J. Nat. Prod. 2002, 65, 1598–1604. [Google Scholar] [CrossRef] [PubMed]
  157. Toghueo, R.M.K.; Boyom, F.F. Endophytic Penicillium species and their agricultural, biotechnological, and pharmaceutical applications. 3 Biotech 2020, 10, 107. [Google Scholar] [CrossRef]
  158. Khan, I.; Zhang, H.; Liu, W.; Zhang, L.; Peng, F.; Chen, Y.; Zhang, Q.; Zhang, G.; Zhang, W.; Zhang, C. Identification and bioactivity evaluation of secondary metabolites from Antarctic-derived Penicillium chrysogenum CCTCC M 2020019. RSC Adv. 2020, 10, 20738–20744. [Google Scholar] [CrossRef]
  159. Ding, Z.; Zhou, H.; Wang, X.; Huang, H.; Wang, H.; Zhang, R.; Wang, Z.; Han, J. Deletion of the Histone Deacetylase HdaA in Endophytic Fungus Penicillium chrysogenum Fes1701 Induces the Complex Response of Multiple Bioactive Secondary Metabolite Production and Relevant Gene Cluster Expression. Molecules 2020, 25, 3657. [Google Scholar] [CrossRef] [PubMed]
  160. Bhatnagar, I.; Kim, S.-K. Immense Essence of Excellence: Marine Microbial Bioactive Compounds. Mar. Drugs 2010, 8, 2673–2701. [Google Scholar] [CrossRef] [Green Version]
  161. Kaleem, S.; Qin, L.; Yi, W.; Lian, X.-Y.; Zhang, Z. Bioactive Metabolites from the Mariana Trench Sediment-Derived Fungus Penicillium sp. SY2107. Mar. Drugs 2020, 18, 258. [Google Scholar] [CrossRef]
  162. Shaala, L.A.; Alzughaibi, T.; Genta-Jouve, G.; Youssef, D.T.A. Fusaripyridines A and B. Highly Oxygenated Antimicrobial Alkaloid Dimers Featuring an Unprecedented 1,4-Bis(2-hydroxy-1,2-dihydropyridin-2-yl)butane-2,3-dione Core from the Marine Fungus Fusarium sp. LY019. Mar. Drugs 2021, 19, 505. [Google Scholar] [CrossRef]
  163. Hua, Y.; Pan, R.; Bai, X.; Wei, B.; Chen, J.; Wang, H.; Zhang, H. Aromatic Polyketides from a Symbiotic Strain Aspergillus fumigatus D and Characterization of Their Biosynthetic Gene D8.t287. Mar. Drugs 2020, 18, 324. [Google Scholar] [CrossRef]
  164. Karim, M.R.U.; Harunari, E.; Sharma, A.R.; Oku, N.; Akasaka, K.; Urabe, D.; Igarashi, Y. Nocarimidazoles C and D, antimicrobial alkanoylimidazoles from a coral-derived actinomycete Kocuria sp.: Application of 1JC, H coupling constants for the unequivocal determination of substituted imidazoles and stereochemical diversity of anteisoalkyl chains in microbial me-tabolites. Beilstein. J. Org. Chem. 2020, 16, 2719–2727. [Google Scholar] [PubMed]
  165. Pérez, M.; Schleissner, C.; Fernández, R.; Rodríguez, P.; Reyes, F.; Zuñiga, P.; de la Calle, F.; Cuevas, C. PM100117 and PM100118, new antitumor macrolides produced by a marine Streptomyces caniferus GUA-06-05-006A. J. Antibiot. 2015, 69, 388–394. [Google Scholar] [CrossRef] [PubMed]
  166. Nuzzo, G.; Cutignano, A.; Sardo, A.; Fontana, A. Antifungal Amphidinol 18 and Its 7-Sulfate Derivative from the Marine Dinoflagellate Amphidinium carterae. J. Nat. Prod. 2014, 77, 1524–1527. [Google Scholar] [CrossRef]
  167. Shaala, L.A.; Youssef, D.T.; Ibrahim, S.R.; Mohamed, G.A.; Badr, J.M.; Risinger, A.L.; Mooberry, S.L. Didemnaketals F and G, new bioactive spiroketals from a Red Sea ascidian Didemnum species. Mar. Drugs 2014, 12, 5021–5034. [Google Scholar] [CrossRef] [Green Version]
  168. López-Abarrategui, C.; Alba, A.; Silva, O.N.; Reyes-Acosta, O.; Vasconcelos, I.M.; Oliveira, J.T.; Migliolo, L.; Costa, M.P.; Costa, C.R.; Silva, M.R.; et al. Functional characterization of a synthetic hydrophilic antifungal peptide derived from the marine snail Cenchritis muricatus. Biochimie 2012, 94, 968–974. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  169. Fedders, H.; Michalek, M.; Grötzinger, J.; Leippe, M. An exceptional salt-tolerant antimicrobial peptide derived from a novel gene family of haemocytes of the marine invertebrate Ciona intestinalis. Biochem. J. 2008, 416, 65–75. [Google Scholar] [CrossRef] [Green Version]
  170. Jang, W.S.; Kim, H.K.; Lee, K.Y.; Kim, S.A.; Han, Y.S.; Lee, I.H. Antifungal activity of synthetic peptide derived from halocidin, antimicrobial peptide from the tunicate, Halocynthia aurantium. FEBS Lett. 2006, 580, 1490–1496. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  171. Kossuga, M.H.; MacMillan, J.B.; Rogers, E.W.; Molinski, T.F.; Nascimento, G.G.; Rocha, R.M.; Berlinck, R.G. (2S,3R)-2-aminododecan-3-ol, a new antifungal agent from the Ascidian Clavelina Oblonga. J. Nat. Prod. 2004, 67, 1879–1881. [Google Scholar] [CrossRef]
  172. Schupp, P.; Poehner, T.; Edrada, R.; Ebel, R.; Berg, A.; Wray, V.; Proksch, P. Eudistomins W and X, two new β-carbolines from the micronesian tunicate Eudistoma sp. J. Nat. Prod. 2003, 66, 272–275. [Google Scholar] [CrossRef]
  173. Alves, A.M.C.V.; Cruz-Martins, N.; Rodrigues, C.F. Marine Compounds with Anti-Candida sp. Activity: A Promised “Land” for New Antifungals. J. Fungi 2022, 8, 669. [Google Scholar] [CrossRef]
Jof 09 00800 g001 550
Figure 1. List of FDA-approved natural products from marine resources and their year of approval. (Source: https://www.marinepharmacology.org/, accessed on 10 July 2023).
Figure 1. List of FDA-approved natural products from marine resources and their year of approval. (Source: https://www.marinepharmacology.org/, accessed on 10 July 2023).
Jof 09 00800 g001
Jof 09 00800 g002 550
Figure 2. Marine organisms for the isolation of different marine natural products.
Figure 2. Marine organisms for the isolation of different marine natural products.
Jof 09 00800 g002
Jof 09 00800 g003 550
Figure 3. Marine natural products from marine sponges. Red circle is an indicative of R group.
Figure 3. Marine natural products from marine sponges. Red circle is an indicative of R group.
Jof 09 00800 g003
Jof 09 00800 g004 550
Figure 4. Marine natural products from marine actinomycetes. Red circle is an indicative of R group.
Figure 4. Marine natural products from marine actinomycetes. Red circle is an indicative of R group.
Jof 09 00800 g004
Jof 09 00800 g005 550
Figure 5. Marine natural products from marine fungi.
Figure 5. Marine natural products from marine fungi.
Jof 09 00800 g005
Table
Table 1. Natural products isolated from the samples of marine sponge and their activity against different Candida spp.
Table 1. Natural products isolated from the samples of marine sponge and their activity against different Candida spp.
CompoundSourceZOI
(mm)		MIC (µg/mL)
and Activities		Target OrganismReference
C1OceanapisideOceanapia phillipensis 10CgDalisay et al., 2021 [27]
C2Oceanalin BOceanapia sp. 25CgMakarieva et al., 2021 [28]
C3Pseudoceroxime APseudoceratina sp. 11.9CaChen et al., 2020 [29]
C4Pseudoceroxime B13
C5Pseudoceroxime C19.80
C6Pseudoceroxime D>20
C7Pseudoceroxime E>20
C8Hippolide JHippospongia lachne 0.125–4Ca, Cp, and CgJiao et al., 2017 [30]
C9Zamamidine DAmphimedon sp. 16CaKubota et al., 2017 [31]
C10Nakamurine AAgelas nakamurai CaChu et al., 2017 [32]
C11Nakamurine B60CaChu et al., 2017 [32]
C12–C14(Z)-5-(4-hydroxybenzylidene)-imidazolidine-2,4-dione, hemimycalins A and BHemimycale arabica22, 14, and 20 CaYoussef et al., 2015 [33]
C15CrambescinPseudaxinella reticulate 11–39; 6.1–17; 11–34Ca, Cg, and CkJamison and Molinski, 2015 [34]
C16Theonellamide GTheonella swinhoei 4.49 and 2.0CaYoussef et al., 2014 [35]
C17Phorbasin H 250
Targeting of yeast-to-hypha transition		CaLee et al., 2013 [36]
C18–C19Nagelamide U and WAgelas sp. 4CaTanaka et al., 2013a [37]
C20–C22Nagelamide X-ZAgelas sp. 0.25 to 2CaTanaka et al., 2013b [38]
C23Aurantoside KMelophlus 31.25 and 1.95CaKumar et al., 2012 [39]
C24Agelasine OAgelas sp. >32CaKubota et al., 2012 [31]
C25Agelasine P>32
C26Agelasine Q16
C27Agelasine R16
C28Agelasine S>32
C29Agelasine T>32
C30Agelasine U>32
C31Woodylide APlakortis simplex 32CaYu et al., 2012 [40]
C32Aurantoside JTheonella swinhoei >16Ca, Cp, Cg, and CtAngawi et al., 2011 [41]
C33Ceratinadin APseudoceratina sp. 2CaKon et al., 2010 [42]
C34Ceratinadin B4
C35Ceratinadin C>32
C36–C37Pseudoceratin
A and B		Pseudoceratina purpurea8 and 6.55-CaJang et al., 2007 [39]
C38Oceanalin AOceanapia sp. 30CgMakarieva et al., 2005 [43]
C393,5-dibromo2-(3,5-dibromo-2-methoxyphenoxy)Dysidea herbacea 7.8, 7.8; 15.62Ca, Ct, and CgSionov et al., 2005 [44]
C40–C419α,11α-epoxycholest-7-ene-3β,5α,6α,19-tetrol 6-acetate and agosterol ADysidea arenaria Targeting of MDR1 and CDR1CaJacob et al., 2003 [45]
C42–C43Bengamide
Bengazole		Pachastrissa sp. 0.8 to 1.5CaFernández et al., 1999 [46]
C44Aurantoside ASiliquariaspongia japonica 1.25CaSata et al., 1999 [47]
C45Aurantoside B0.63
C46Aurantoside D9.5
C47Aurantoside E0.16
C48Aurantoside FInactive
C49Microsclerodermin CTheonella sp. 5CaSchmidt, E. W., and Faulkner, 1998 [48]
C50Cyclolithistide ATheonella swinhoei 20CaClark et al., 1998 [49]
C51–C52Phorboxazoles
A and B		Phorbas sp.12 CaSearle et al., 1995 [50]
C53TheonegramideTheonella swinhoei10 CaBewley, C. A., and Faulkner, 1994 [51]
C54Theonellamide FTheonella sp. 3–12unspecific Candida spp.Matsunaga et al., 1989 [52]
C55HalichondramideHalichondria sp. 0.2CaKernan et al., 1987 [53]
Ca: Candida albicans; Ct: Candida tropicalis; Ck: Candida krusei; Cp: Candida parapsilosis; Cg: Candida glabrata; ZOI—zone of inhibition; MIC—minimum inhibitory concentration.
Table
Table 2. Natural products isolated from the samples of marine algae and their activity against different Candida spp.
Table 2. Natural products isolated from the samples of marine algae and their activity against different Candida spp.
CompoundSourceZOI
(mm)		MIC (µg/mL) and ActivitiesTarget OrganismReference
Crude extractChampia parvula13.8 ± 0.08 and 16.7 ± 0.15 Ca, CtGanesan 2019 [67]
C67(9Z,12Z,15Z,18Z,21Z)-ethyl tetracosa-9,12,15,18,21- pentaenoateLaurencia okamurai 4CgFeng et al., 2015 [68]
C68MahoroneAsparagopsis taxiformis >32CaGreff et al., 2014 [69]
C695-bromomahorone>32
C70LaurepoxyeneLaurencia okamurai 2CgYu et al., 2014 [70]
C713b-Hydroperoxyaplysin4
C723a-Hydroperoxy-3-epiaplysin>64
C738,10-Dibromoisoaplysin>64
C74(5S)-5-Acetoxy-b-bisabolene64
C7510-Bromoisoaplysin32
C76Laurokamurene C1
C77Laurokamurene A64
C78PhlorotanninCystoseira nodicaulis Cystoseira usneoides and Fucus spiralis 15.6 and 31.3; 31.3 and >62.5Ca; CkLopes et al., 2013 [71]
C79Caulerprenylol BCaulerpa racemosa 4CgLiu et al., 2013 [72]
C80Bromophycolide U >15CaLin et al., 2010 [73]
C81IsolauraldehydeLaurencia obtusa 70CaAlarif et al., 2012 [74]
C8212-hydroxy isolaurene 2000
C838,11-dihydro-12-hydroxy isolaurene 120
C84Symphyocladin GSymphyocladia latiuscula 10CaXu et al., 2012 [75]
C85Bromophycolide RCallophycus serratus >15CaLin et al., 2010 [73]
C86Bromophycolide S>15
C87Bromophycolide T>15
C882,20,3,30-tetrabromo-4,40,5,50-tetrahydroxydiphenylmethaneOdonthalia corymbifera 1.56CaOh et al., 2008 [76]
C89–C90Capisterones A and BPenicillus capitatus CDR1 efflux pump activityCaLi et al., 2006 [77]
C91AcetoxyfimbrolideDelisea pulchra17 CaAnkisetty et al., 2004 [78]
Ca: Candida albicans; Ct: Candida tropicalis; Ck: Candida krusei; Cp: Candida parapsilosis; Cg: Candida glabrata; ZOI—zone of inhibition; MIC—minimum inhibitory concentration.
Table
Table 3. Natural products isolated from the samples of sea cucumber and their activity against different Candida spp.
Table 3. Natural products isolated from the samples of sea cucumber and their activity against different Candida spp.
CompoundGroupSourceZOI
(mm)		MIC
(µg/mL)		Target OrganismReference
C94
C95
C96
C97
C98		Coloquadranoside A
Philinopside A
Philinopside B
Philinopside E
Pentactaside B		Triterpene glycosidesColochirus quadrangularis 4, 8, 4
20, 30, 32
4, 8, 4
4, 8, 4
25		Ca, Ct, and CpYang et al., 2021 [79]
C99–C108Cousteside A-JNon-sulfated triterpene glycosidesBohadschia cousteaui10.7 ± 0.05 to 18.0 ± 0.01 CaElbandy et al., 2014 [80]
C109
C110
C111
C112
C113
C114		Variegatuside C
Variegatuside D
Variegatuside E
Variegatuside F
Variegatuside A
Variegatuside B		Triterpene glycosidesStichopus variegates Semper 12.5; 25; 12.5
3.4; 3.4; 13.6
25; 12.5; 12.5
25; 12.5; 12.5
25; 12.5; 12.5
100; 25; >125		Ca, Cp, and CtWang et al., 2014 [81]
C11526-Nor-25-oxo-holotoxin A1Triterpene glycosidesApostichopus japonicus Selenka >45.91Ca and CtWang et al., 2012 [82]
C116Holotoxin D6.64, 13.29
C117Holotoxin E13.45, 13.45
C118Holotoxin F5.58, 5.68
C119Holotoxin G5.81, 5.81
C120Holotoxin A111.49, 5.68
C121Holotoxin B11.36, 5.68
C122Cladoloside B3.28, 1.64
C123Arguside FTriterpene glycosidesHolothuria (Microthele) axiloga 64, 16, 16Ca, Ct, and CkYuan et al., 2009a [83]
C124Impatienside B4, 4, 4
C125Pervicoside D64, 16, 16
C126
C127
C128
C129
C130
C131		Marmoratoside A
Marmoratoside B
17α-hydroxy impatienside A
25-acetoxy
bivittoside D
Impatienside A Bivittoside D		Triterpene glycosidesBohadschia marmorata 2.81; 2.81; 11.24
2.78; 2.78; 2.78
44.44; 44.44; 44.44
43.13; 10.78; 10.78
2.81; 2.81; 2.81
2.80; 2.80; 2.80		Ca, Ct, and CkYuan et al., 2009b [84]
C132Axilogoside A (132)Triterpene glycosideHolothuria (Microthele) axiloga 16CaWei-Hua et al., 2008 [85]
C133Holothurin B (133)Triterpene glycosideActinopyga lecanora 25, 12.5 and 6.25Ca, Ck, and CpKumar et al., 2007 [86]
Ca: Candida albicans; Ct: Candida tropicalis; Ck: Candida krusei; Cp: Candida parapsilosis; Cg: Candida glabrata; ZOI—zone of inhibition; MIC—minimum inhibitory concentration.
Table
Table 4. Natural products isolated from the samples of marine actinomycetes and their activity against different Candida spp.
Table 4. Natural products isolated from the samples of marine actinomycetes and their activity against different Candida spp.
CompoundGroupSourceZOI
(mm)		MIC (µg/mL) and ActivitiesTarget OrganismReference
C134
C135
C136
C137
C138
C139		Chainin
Filipin IX
Filipin XI
Filipin XII
Filipin II
Filipin III		Deep-sea actinobacteriaStreptomyces antibioticus OUCT16-2 1.56–12.5CaBao et al., 2022 [92]
C140Antimycin ISponge-associatedStreptomyces sp. NBU3104 8CaLi et al., 2022 [93]
C141–C143Iseolide A–CCoral-derivedStreptomyces sp. 0.39–6.25CaZhang et al., 2020 [94]
C144Tunicamycin C3Deep seaStreptomyces xinghaiensis SCSIO S15077 4–32CaZhang et al., 2020 [95]
C145MaculosinCosta soilStreptomyces sp. ZZ446 27CaChen et al., 2020 [61]
C146Maculosin-O-a-L rhamnopyranoside 26
C147Rubromycin CA1TunicateStreptomyces hyaluromycini 6.3CaHarunari et al., 2019 [96]
C148–C151Caniferolide A-D Streptomyces caniferus CA-271066 0.5 to 2.0CaPérez-Victoria et al., 2019 [97]
C152–
C153		13(α)-Acetoxy-anhydroisoheximide and 13(β)-acetoxy-anhydroisoheximidDeep seaStreptomyces sp. YG7 62.5CaPan 2019 [98]
C154–C156Nitricquinomycin
A-C		Marine-sediment-derivedStreptomyces sp. ZS-A45 >40CaZhou et al., 2019 [99]
C157–C160Streptopyrazinone A-DCostal soilStreptomyces sp. ZZ446 35–60CaChen et al., 2018 [100]
C161N-acetyl-L-isoleucine-L-leucinamide
C162–C165Strepoxepinmycin
A–D		Marine environmentStreptomyces sp. XMA39 5 to 10CaJiang et al., 2018 [101]
C166–C168Kitamycin A-C Streptomyces antibioticus strain 200-09 25CaWang et al., 2017 [102]
C169Urauchmycin B
C170Deisovaleryblastomycin
C171Rocheicoside AMarine-sediment-derivedStreptomyces rochei 06CM01637 CaAksoy et al., 2016 [103]
C172–C173Mohangamide
A and B		Marine actinomyceteStreptomyces sp.inhibiting isocitrate lyaseIC50 = 4.4 and 20.5 µMCaBae et al. 2015 [104]
C174–C175Reedsmycin A and F Streptomyces sp. CHQ-64 25–50CaChe et al., 2015 [105]
C17628-N-MethylikaguramycinMarine sedimentStreptomyces zhaozhouensis CA-185989 4
CaLacret et al., 2014 [106]
C177Isoikarugamycin2–4
C178Ikarugamycin4
C179Caerulomycin AMarine actinomycetesActinoalloateichus cyanogriseus 0.39–0.78; 0.78–1.56Ca, Cg, and CkAmbavane et al., 2014 [107]
C180ArcticosideArctic ActinomyceteStreptomyces sp.Inhibition of C. albicans Isocitrate Lyase30.4 μMCaMoon et al., 2014 [108]
C181Bahamaolide AMarine actinomyceteStreptomyces sp. 12.5CaKim et al. 2012 [109]
C182(N-(2-hydroxyphenyl)-2-phenazinamine)Arctic sedimentNocardia dassonvillei 64CaGao et al., 2012 [110]
C183Azalomycin F4a 2-ethylpentyl esterMangrove rhizosphere soilStreptomyces sp. 211726 2.34 and 12.5CaYuan et al., 2013 [111]
C184Azalomycin F5a 2-ethylpentyl ester
C185–C186Antimycins
A19 and A20		 Streptomyces antibioticus H74-18 5 to 10CaXu et al., 2011 [112]
C187SaadamycinEgyptian sponge Aplysina fistularisStreptomyces sp. Hedaya48 2.22 and 15CaEl-Gendy and EL-Bondkly, 2010 [113]
C1885,7-Dimethoxy-4-p-methoxylphenylcoumarin
C189ChitinaseSponge associateStreptomyces sp. DA1110.48 ± 0.45-CaHan et al., 2009 [114]
C190CaboxamycinDeep sea cold waterStreptomyces sp. NTK 937-117CgHohmann et al., 2009 [115]
C191Piperazimycin BMarine-derivedStreptomyces sp. 14-CaShaaban et al., 2008 [116]
Ca: Candida albicans; Ct: Candida tropicalis; Ck: Candida krusei; Cp: Candida parapsilosis; Cg: Candida glabrata; ZOI—zone of inhibition; MIC—minimum inhibitory concentration.
Table
Table 5. Natural products isolated from the samples of marine bacteria and their activity against different Candida sp.
Table 5. Natural products isolated from the samples of marine bacteria and their activity against different Candida sp.
CompoundGroupSourceZOI (mm)MIC (µg/mL)Target OrganismReference
C192
C204
C205
Cycloprodigiosin
Prodigiosin
2-Methyl-3-hexyl prodiginine		Red marine bacteriumPseudoalteromonas rubra7.9 ± 0.07, 8.2 ± 0.09 7.9 ± 0.06 CaSetiyono et al., 2020 [123]
C193–C195Bulbimidazole A−C Gammaproteobacterium Microbulbifer 6.25–12.5CaKarim et al., 2020 [124]
C196
C197		Indolepyrazine A
Indolepyrazine B		Marine bacteriaAcinetobacter sp. ZZ1275 12 and 14CaAnjum et al., 2019 [125]
C198
C199		Janthinopolyenemycin A Janthinopolyenemycin BMarine bacteriaJanthinobacterium spp. ZZ145 and ZZ148 15.6CaAnjum et al., 2018 [126]
C200
C201		Ieodoglucomide C
Ieodoglycolipid		Marine bacteriaBacillus licheniformis 09IDYM23 0.05 and 0.03CaTareq et al., 2015 [127]
C202
C203		Forazoline A
Forazoline B		Invertebrate-associated bacteria 16CaWyche et al., 2014 [128]
C204–C210
Gageomacrolactin A-C, macrolactins A (C207), B (C208), E (C209) and W (C210)Marine sedimentsBacillus subtilis 0.05–0.15CaTareq et al., 2013 [129]
C211–218Quinazolinones (in total 8 analogues)Marine bacteriumBacillu cereus 041381 1.3–15.6CaXu et al., 2011 [130]
C219Pedein A Chondromyces pediculatus321.6CaKunze et al. 2008 [131]
C2202-Nitro-4-(2′-nitroethenyl)-phenolArctic sea ice bacteriumSalegentibacter sp. T436 20CaAl-Zereini et al. 2007 [132]
C221Hassallidin ACyanobacteriumHassallia sp. 4.8CaNeuhof et al., 2005 [133]
C222
C223		Basiliskamide A
Basiliskamide B		Tropical marine habitatBacillus laterosporus 1.0
3.1		CaBarsby et al., 2002 [134]
C224–C226Lobocyclamide A-CCyanobacterial matLyngbya confervoides7–10 and 6–8 Ca and CgMacMillan et al., 2002 [135]
Ca: Candida albicans; Ct: Candida tropicalis; Ck: Candida krusei; Cp: Candida parapsilosis; Cg: Candida glabrata; ZOI—zone of inhibition; MIC—minimum inhibitory concentration.
Table
Table 6. Natural compounds isolated from the samples of marine fungi and their activity against different Candida spp.
Table 6. Natural compounds isolated from the samples of marine fungi and their activity against different Candida spp.
CompoundGroupSourceZOI (mm)MIC (µg/mL)Target organismReference
C227
C228		Ditalaromylectone A
Altenusin		 Talaromyces mangshanicus BTBU20211089 200CaZhang et al., 2022 [136]
C229ent-EpiheveadrideMarine sedimentAspergillus chevalieri PSU-AMF79 200CaNingsih et al., 2022 [137]
C230(-)-Massoia lactoneUnidentified tunicateTrichoderma harzianum PSU-MF79 200CaNuansri et al., 2021 [138]
C231Talaroisocoumarin AMarine-derived fungiTalaromyces sp. ZZ1616 26CaMingzhu Ma et al., 2020 [139]
C232Emethacin CTissue of sea hare aplysia pulmonicaAspergillus terreus 32CaWu et al., 2020 [140]
C233–C235Trichobreol A-CMarine red algaTrichoderma cf. brevicompactum 3.1- 50CaYamazaki et al. 2020 [141]
C236Atranone QMarine fungusStachybotrys chartarum 8CaYang et al., 2019 [142]
C237Terretrione CTunicate-derived fungusPenicillium sp. 1932CaShaala LA and Youssef DT 2015 [143]
C238
C239		Asperfurandione A
Asperfurandione B		Deep-sea fungiAspergillus versicolor 64CaDing et al., 2019 [144]
C240–C247Cladosporiumin A-H Cladosporium sp. SCSIO z0025 Anti-biofilmCaHuang et al., 2018 [145]
C248Eutypellenoid BArctic fungusEutypella sp. 8, 16 and 32Ca, Cg, and CtYu et al., 2018 [146]
C249–C255Pyrrospirones C-IMarine-derived fungusPenicillium sp. ZZ380. No activityCaSong et al., 2018 [147]
C256Nigerasperone CMarine brown algaAspergillus niger EN-139.0-CaZhang et al., 2007 [148]
C257PenicillenolMarine sedimentAspergillus restrictus DFFSCS006 >200CaWang et al., 2017 [149]
C258
C259		Penicillenol A2
Penicillenol B1		Marine sedimentAspergillus restrictus DFFSCS006 Inhibit the biofilm growth and hyphae-related genesCaWang et al., 2017 [149]
C260Melearoride AMarine-derived fungusPenicillium meleagrinum var. viridiflavum >32CaOkabe et al., 2016 [150]
C261PF1163A1
C262PF1163B2
C263PF1163D>32
C264PF1163H16
C265PF1163F8
C266Melearoride B>32
C267
C268		Pleosporallin D
Pleosporallin E		Marine alga Enteromorpha clathrataPleosporales sp. >10
7.44		CaChen et al., 2015 [151]
C269Dendrodochol ASea cucumberDendrodochium sp. 16, 16, 16Ca, Cp, and CgXu et al., 2014 [152]
C270Dendrodochol B16, >64, >64
C271Dendrodochol C16, 16, 8
C272Dendrodochol D> 64 all
C273Didymellamide AMarine-sponge-associatedStagonosporopsis cucurbitacearum 3.1; 3.1Ca and CgHaga et al., 2013 [153]
C274Citrafungin AMarine fungiAspergillus aculeatus 0.43CaSingh 2004 [154]
C275
C276		Sporiolide A
Sporiolide B		Brown alga Actinotrichia fragilisCladosporium sp. 16.7
>33.33		CaShigemori et al., 2004 [155]
C277Xestodecalactone AMarine-sponge-associatedPenicillium cf. montanense7, 12 and 2520, 50 and 100CaEdrada et al., 2002 [156]
Ca: Candida albicans; Ct: Candida tropicalis; Ck: Candida krusei; Cp: Candida parapsilosis; Cg: Candida glabrata; ZOI—zone of inhibition; MIC—minimum inhibitory concentration.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ganeshkumar, A.; Gonçale, J.C.; Rajaram, R.; Junqueira, J.C. Anti-Candidal Marine Natural Products: A Review. J. Fungi 2023, 9, 800. https://doi.org/10.3390/jof9080800

AMA Style

Ganeshkumar A, Gonçale JC, Rajaram R, Junqueira JC. Anti-Candidal Marine Natural Products: A Review. Journal of Fungi. 2023; 9(8):800. https://doi.org/10.3390/jof9080800

Chicago/Turabian Style

Ganeshkumar, Arumugam, Juliana Caparroz Gonçale, Rajendran Rajaram, and Juliana Campos Junqueira. 2023. "Anti-Candidal Marine Natural Products: A Review" Journal of Fungi 9, no. 8: 800. https://doi.org/10.3390/jof9080800

APA Style

Ganeshkumar, A., Gonçale, J. C., Rajaram, R., & Junqueira, J. C. (2023). Anti-Candidal Marine Natural Products: A Review. Journal of Fungi, 9(8), 800. https://doi.org/10.3390/jof9080800

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop